Nutex Health (NUTX) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 04, 2024
Cover
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Securities Act File Number	001-41346
Entity Registrant Name	NUTEX HEALTH INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3363609
Entity Address, Address Line One	6030 S. Rice Ave
Entity Address, Address Line Two	Suite C
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77081
City Area Code	713
Local Phone Number	660-0557
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	NUTX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,437,003
Entity Central Index Key	0001479681
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 46,909,281	$ 22,002,056
Accounts receivable	62,745,336	58,624,301
Accounts receivable - related parties	3,602,189	4,152,068
Inventories	2,259,168	3,390,584
Prepaid expenses and other current assets	4,279,360	2,679,394
Total current assets	119,795,334	90,848,403
Property and equipment, net	78,246,467	81,387,649
Operating right-of-use assets	11,442,369	11,853,082
Finance right-of-use assets	198,462,381	176,146,329
Intangible assets, net	15,855,392	20,512,636
Goodwill, net	13,918,719	17,066,263
Other assets	767,942	431,135
Total assets	438,488,604	398,245,497
Current liabilities:
Accounts payable	10,320,933	18,899,196
Accounts payable - related parties	6,342,883	6,382,197
Lines of credit	3,384,517	3,371,676
Current portion of long-term debt	10,499,532	10,808,721
Operating lease liabilities, current portion	2,060,758	1,579,987
Finance lease liabilities, current portion	5,261,458	4,315,979
Accrued expenses and other current liabilities	29,688,665	12,955,296
Total current liabilities	67,558,746	58,313,052
Long-term debt, net	26,801,811	26,314,733
Warrant liability	5,715,143
Operating lease liabilities, net	14,307,320	15,479,639
Finance lease liabilities, net	240,924,194	213,886,213
Deferred tax liabilities	3,402,965	5,145,754
Total liabilities	358,710,179	319,139,391
Commitments and contingencies
Equity:
Common stock, $0.001 par value; 950,000,000 shares authorized; 5,215,709 and 4,511,199 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	5,216	4,511
Additional paid-in capital	479,024,452	470,521,218
Accumulated deficit	(418,588,975)	(409,072,539)
Nutex Health Inc. equity	60,440,693	61,453,190
Noncontrolling interests	19,337,732	17,652,916
Total equity	79,778,425	79,106,106
Total liabilities and equity	$ 438,488,604	$ 398,245,497

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value	$ 0.001	$ 0.001
Common stock authorized	950,000,000	950,000,000
Common stock issued	5,215,709	4,511,199
Common stock outstanding	5,215,709	4,511,199

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Total revenue	$ 78,794,869	$ 62,722,972	$ 222,330,917	$ 177,976,843
Operating costs and expenses:
Payroll and benefits	29,848,083	28,873,144	85,249,302	79,570,519
Contract services	11,657,010	9,035,650	32,481,686	27,972,854
Medical supplies	3,982,598	3,460,130	12,892,904	10,748,214
Depreciation and amortization	4,972,478	4,745,941	13,691,484	12,908,848
Other	6,417,886	9,541,894	23,380,318	25,215,549
Total operating costs and expenses	56,878,055	55,656,759	167,695,694	156,415,984
Gross profit	21,916,814	7,066,213	54,635,223	21,560,859
Corporate and other costs:
Facilities closing costs				217,266
Acquisition costs		43,464		43,464
Stock-based compensation expense	1,963,518	49,167	1,951,444	2,198,812
Impairment of assets	425,221		3,898,856
Impairment of goodwill			3,197,391
General and administrative expenses	9,865,330	7,794,808	29,176,130	24,730,168
Total corporate and other costs	12,254,069	7,887,439	38,223,821	27,189,710
Operating income (loss)	9,662,745	(821,226)	16,411,402	(5,628,851)
Interest expense, net	5,381,040	4,098,179	14,879,934	12,081,316
Loss on warrant liability	6,733,552		1,072,709
Other (income) expense	128,645	(53,206)	(712,049)	70,721
Income (loss) before taxes	(2,580,492)	(4,866,199)	1,170,808	(17,780,888)
Income tax expense (benefit)	4,584,518	(342,259)	5,868,075	(2,068,530)
Net loss	(7,165,010)	(4,523,940)	(4,697,267)	(15,712,358)
Less: net income (loss) attributable to noncontrolling interests	1,623,303	1,018,451	4,819,169	(1,543,641)
Net loss attributable to Nutex Health Inc.	$ (8,788,313)	$ (5,542,391)	$ (9,516,436)	$ (14,168,717)
Loss per common share:
Basic, Loss per common share (in dollar per share)	$ (1.72)	$ (1.25)	$ (1.91)	$ (3.23)
Diluted, Loss per common share (in dollar per share)	$ (1.72)	$ (1.25)	$ (1.91)	$ (3.23)
Hospital division
Revenue:
Total revenue	$ 71,732,529	$ 54,585,263	$ 199,366,776	$ 155,485,230
Population health management division
Revenue:
Total revenue	$ 7,062,340	$ 8,137,709	$ 22,964,141	$ 22,491,613

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Noncontrolling Interests	Total
Beginning balance, value at Dec. 31, 2022	$ 4,335	$ 459,144,291	$ (363,285,925)	$ 24,464,699	$ 120,327,400
Beginning balance, shares at Dec. 31, 2022	4,334,826
Deconsolidation of Real Estate Entities				(4,258,133)	(4,258,133)
Common stock issued for exercise of warrants	$ 5	(5)
Common stock issued for exercise of warrants (in shares)	4,682
Common stock issuance	$ 7	1,899,993			1,900,000
Common stock issuance (in shares)	6,667
Contributions				28,000	28,000
Distributions				(1,537,141)	(1,537,141)
Net income (loss)			(5,147,279)	(1,774,693)	(6,921,972)
Ending balance, value at Mar. 31, 2023	$ 4,347	461,044,279	(368,433,204)	16,922,732	109,538,154
End balance, shares at Mar. 31, 2023	4,346,175
Beginning balance, value at Dec. 31, 2022	$ 4,335	459,144,291	(363,285,925)	24,464,699	120,327,400
Beginning balance, shares at Dec. 31, 2022	4,334,826
Common stock issuance					1,900,000
Common stock issued for acquisition					750,000
Net income (loss)					(15,712,358)
Ending balance, value at Sep. 30, 2023	$ 4,472	467,377,960	(377,454,642)	14,976,943	104,904,733
End balance, shares at Sep. 30, 2023	4,471,411
Beginning balance, value at Mar. 31, 2023	$ 4,347	461,044,279	(368,433,204)	16,922,732	109,538,154
Beginning balance, shares at Mar. 31, 2023	4,346,175
Common stock issued for exercise of warrants	$ 4	(4)
Common stock issued for exercise of warrants (in shares)	3,774
Debt conversion to common stock	$ 53	3,232,386			3,232,439
Debt conversion to common stock (in shares)	53,571
Restricted stock awards issued for compensation	$ 1	249,644			249,645
Restricted stock awards issued for compensation (in shares)	1,431
Contributions				621,550	621,550
Distributions				(1,149,163)	(1,149,163)
Net income (loss)			(3,479,047)	(787,399)	(4,266,446)
Ending balance, value at Jun. 30, 2023	$ 4,405	464,526,305	(371,912,251)	15,607,720	108,226,179
End balance, shares at Jun. 30, 2023	4,404,951
Debt conversion to common stock	$ 50	1,919,021			1,919,071
Debt conversion to common stock (in shares)	49,517
Common stock issued for acquisition	$ 17	749,983			750,000
Common stock issued for acquisition (in shares)	16,943
Stock-based compensation		49,167			49,167
Distributions				(1,649,228)	(1,649,228)
Warrants issued with convertible debt		133,484			133,484
Net income (loss)			(5,542,391)	1,018,451	(4,523,940)
Ending balance, value at Sep. 30, 2023	$ 4,472	467,377,960	(377,454,642)	14,976,943	104,904,733
End balance, shares at Sep. 30, 2023	4,471,411
Beginning balance, value at Dec. 31, 2023	$ 4,511	470,521,218	(409,072,539)	17,652,916	79,106,106
Beginning balance, shares at Dec. 31, 2023	4,511,199
Common stock issued for Employee Stock Purchase Plan	$ 2	19,024			19,026
Common stock issued for Employee Stock Purchase Plan (in shares)	746
Common stock issuance	$ 444	1,540,499			1,540,943
Common stock issuance (in shares)	444,444
Debt conversion to common stock	$ 12	320,676			320,688
Debt conversion to common stock (in shares)	11,824
Stock-based compensation		49,167			49,167
Vesting of Restricted Stock Units	$ 1	(1)
Vesting of Restricted Stock Units (in shares)	1,298
Reverse stock split adjustment	$ 2	(2)
Reverse stock split adjustment (in shares)	2,426
Distributions				(481,293)	(481,293)
Net income (loss)			(364,075)	(178,412)	(542,487)
Ending balance, value at Mar. 31, 2024	$ 4,972	472,450,581	(409,436,614)	16,993,211	80,012,150
End balance, shares at Mar. 31, 2024	4,971,937
Beginning balance, value at Dec. 31, 2023	$ 4,511	470,521,218	(409,072,539)	17,652,916	79,106,106
Beginning balance, shares at Dec. 31, 2023	4,511,199
Common stock received in sale of business					(30,250)
Common stock issued for acquisition					406,158
Reverse stock split adjustment					3
Net income (loss)					(4,697,267)
Ending balance, value at Sep. 30, 2024	$ 5,216	479,024,452	(418,588,975)	19,337,732	79,778,425
End balance, shares at Sep. 30, 2024	5,215,709
Beginning balance, value at Mar. 31, 2024	$ 4,972	472,450,581	(409,436,614)	16,993,211	80,012,150
Beginning balance, shares at Mar. 31, 2024	4,971,937
Common stock received in sale of business	$ (5)	(30,245)			(30,250)
Common stock received in sale of business (in shares)	(5,060)
Common stock issued for Employee Stock Purchase Plan	$ 2	14,407			14,409
Common stock issued for Employee Stock Purchase Plan (in shares)	2,061
Common stock issued for acquisition	$ 18	156,140			156,158
Common stock issued for acquisition (in shares)	17,640
Stock-based compensation		(61,241)			(61,241)
Reverse stock split adjustment	$ 1	(1)
Reverse stock split adjustment (in shares)	690
Contributions				300,850	300,850
Distributions				(1,380,270)	(1,380,270)
Net income (loss)			(364,048)	3,374,278	3,010,230
Ending balance, value at Jun. 30, 2024	$ 4,988	472,529,641	(409,800,662)	19,288,069	82,022,036
End balance, shares at Jun. 30, 2024	4,987,268
Common stock issued for Employee Stock Purchase Plan	$ 4	25,366			25,370
Common stock issued for Employee Stock Purchase Plan (in shares)	4,300
Common stock issued for acquisition	$ 47	249,953			250,000
Common stock issued for acquisition (in shares)	47,106
Stock-based compensation	$ 27	1,963,481			1,963,508
Stock-based compensation (in shares)	27,035
Contributions		436,038		224,025	660,063
Distributions				(1,797,665)	(1,797,665)
Warrant exercises	$ 150	3,819,973			3,820,123
Warrant exercises (in shares)	150,000
Net income (loss)			(8,788,313)	1,623,303	(7,165,010)
Ending balance, value at Sep. 30, 2024	$ 5,216	$ 479,024,452	$ (418,588,975)	$ 19,337,732	$ 79,778,425
End balance, shares at Sep. 30, 2024	5,215,709

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ (4,697,267)	$ (15,712,358)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization	13,691,484	12,908,848
Loss on warrant liability	1,072,709
Impairment of goodwill	3,197,391
Impairment of assets	3,898,856
Derecognition of goodwill	453,017
Stock-based compensation expense	1,951,444	2,198,812
Deferred tax benefit	(1,742,789)	(2,068,530)
Debt accretion expense	804,760	1,251,867
Loss on lease termination		58,210
Non-cash lease expense (income)	(280,835)	89,338
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable	(4,253,034)	4,444,706
Accounts receivable - related party	549,879	(949,408)
Inventories	1,131,416	850,569
Prepaid expenses and other current assets	(1,360,721)	(3,771,946)
Accounts payable	(7,975,067)	(6,015,250)
Accounts payable - related party	(39,314)	2,228,527
Accrued expenses and other current liabilities	16,698,416	7,519,285
Net cash from operating activities	23,100,345	3,032,670
Cash flows from investing activities:
Acquisitions of property and equipment	(1,908,651)	(10,322,487)
Cash related to sale of business	(361,325)
Payments for acquisitions of businesses, net of cash acquired		(743,837)
Cash related to deconsolidation of Real Estate Entities		(1,039,157)
Net cash from investing activities	(2,269,976)	(12,105,481)
Cash flows from financing activities:
Proceeds from lines of credit	1,132,168	2,340,911
Proceeds from notes payable	7,014,999	16,952,905
Proceeds from convertible notes		891,000
Repayments of lines of credit	(1,119,327)	(1,592,714)
Repayments of notes payable	(8,332,482)	(10,557,758)
Repayments of finance leases	(1,923,687)	(2,704,082)
Proceeds from common stock issuance, net issuance costs	9,202,500
Proceeds from exercise of warrants	801,000
Members' contributions	960,913	649,550
Members' distributions	(3,659,228)	(4,335,532)
Net cash from financing activities	4,076,856	1,644,280
Net change in cash and cash equivalents	24,907,225	(7,428,531)
Cash and cash equivalents - beginning of the period	22,002,056	34,255,264
Cash and cash equivalents - end of the period	$ 46,909,281	$ 26,826,733

Organization and Operations

Organization and Operations	9 Months Ended
	Sep. 30, 2024
Organization and Operations
Organization and Operations	Note 1 – Nutex Health Inc. (“Nutex Health” or the “Company”), is a physician-led, healthcare services and operations company with 22 hospital facilities in ten states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates different innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (“HOPDs”). The population health management division owns and operates provider networks such as independent physician associations (“IPAs”). We employ approximately 800 full time employees, contract 230 doctors at our facilities and partner with over 1,700 physicians within our networks. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware. Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc ​ In connection with the Merger Agreement, Nutex Health Holdco LLC entered into certain Contribution Agreements with holders of equity interests (“Nutex Owners”) of subsidiaries and affiliates (the “Nutex Subsidiaries”) pursuant to which such Nutex Owners agreed to contribute certain equity interests in the Nutex Subsidiaries to Nutex Health Holdco LLC in exchange for specified equity interests in Nutex Health Holdco LLC (collectively, the “Contribution Transaction”). Nutex owners having ownership interests representing approximately 84% of the agreed upon aggregate equity value of the Nutex Subsidiaries, agreed to contribute all or a portion of their equity interests, as applicable. ​ Pursuant to the Merger Agreement, each unit representing an equity interest in Nutex Health Holdco LLC issued and outstanding immediately prior to the effective time of the Merger but after the Contribution Transaction (collectively, the “Nutex Membership Interests”) was converted into the right to receive 3.571428575 shares of common stock of Clinigence, or an aggregate of 592,791,712 shares of common stock of Clinigence. ​ After completing the merger, Clinigence was renamed Nutex Health Inc. 2024 Reverse Stock Splits. 1:15 Reverse stock split. 1 1 1 1 -1 1 1:10 Reverse stock split. 1 1 1 1 1 1 -1 trading symbol “NUTX” at the open of the market on July 3, 2024. The 1 As a result of both the 1 1 Unless otherwise indicated, all authorized, issued, and outstanding stock and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted to reflect the 2024 Reverse Stock Splits for all prior periods presented. The impacts of the 2024 Reverse Stock Splits were applied retroactively for all periods presented in accordance with applicable guidance. Therefore, prior period amounts are different than those previously reported. Certain amounts within the following tables may not foot due to rounding. ​ The following table illustrates changes in equity, as previously reported prior to, and as adjusted subsequent to, the impact of the 2024 Reverse Stock Splits retroactively adjusted for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common Stock - Shares ​ ​ 670,711,741 ​ ​ (666,240,330) ​ ​ 4,471,411 Common Stock - Amount ​ $ 670,712 ​ $ (666,240) ​ $ 4,472 Additional Paid-in Capital ​ $ 466,711,720 ​ $ 666,240 ​ $ 467,377,960 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common Stock - Shares ​ ​ 676,679,911 ​ ​ (672,168,712) ​ ​ 4,511,199 Common Stock - Amount ​ $ 676,680 ​ $ (672,169) ​ $ 4,511 Additional Paid-in Capital ​ $ 469,849,049 ​ $ 672,169 ​ $ 470,521,218 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common Stock - Shares ​ ​ 650,223,840 ​ ​ (645,889,014) ​ ​ 4,334,826 Common Stock - Amount ​ $ 650,224 ​ $ (645,889) ​ $ 4,335 Additional Paid-in Capital ​ $ 458,498,402 ​ $ 645,889 ​ $ 459,144,291 ​ The following table illustrates changes in loss per share and weighted average shares outstanding, as previously reported prior to, and as adjusted subsequent to, the impact of the 2024 Reverse Stock Splits retroactively adjusted for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Loss attributable to common stockholders ​ $ (5,542,391) ​ $ - ​ $ (5,542,391) Weighted average shares used to compute basic and diluted EPS ​ ​ 665,055,603 ​ ​ (660,621,899) ​ ​ 4,433,704 Loss per share - basic and diluted ​ $ (0.01) ​ $ (1.23) ​ $ (1.25) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Loss attributable to common stockholders ​ $ (14,168,717) ​ $ - ​ $ (14,168,717) Weighted average shares used to compute basic and diluted EPS ​ ​ 657,590,265 ​ ​ (653,206,330) ​ ​ 4,383,935 Loss per share - basic and diluted ​ $ (0.01) ​ $ (3.22) ​ $ (3.23) ​ The following outstanding stock options and warrants exercisable or issuable into shares of common stock were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three and nine months ended September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common stock options ​ ​ 5,147,770 ​ ​ (5,113,452) ​ ​ 34,318 Common stock warrants ​ ​ 10,811,062 ​ ​ (10,738,988) ​ ​ 72,074 ​ Stock options were adjusted retroactively to give effect to the 2024 Reverse Stock Splits for the nine months ended September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Previously Reported ​ Impact of the 2024 Reverse Stock Splits ​ Revised ​ ​ Options ​ Weighted Average ​ Options ​ Weighted Average ​ Options ​ Weighted Average ​ ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price Options outstanding at December 31, 2022 ​ ​ 5,147,770 ​ $ 2.30 ​ ​ (5,113,452) ​ $ 342.70 ​ ​ 34,318 ​ $ 345.00 Options exercised ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Options cancelled ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Options outstanding at September 30, 2023 ​ ​ 5,147,770 ​ $ 2.30 ​ ​ (5,113,452) ​ $ 342.70 ​ ​ 34,318 ​ $ 345.00 ​ Warrants were adjusted retroactively to give effect to the 2024 Reverse Stock Splits for the nine months ended September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Previously Reported ​ Impact of the 2024 Reverse Stock Splits ​ Revised ​ ​ Warrants ​ Weighted Average ​ Warrants ​ Weighted Average ​ Warrants ​ Weighted Average ​ ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price Warrants outstanding at December 31, 2022 ​ ​ 11,033,015 ​ $ 1.96 ​ ​ (10,959,462) ​ $ 292.20 ​ ​ 73,553 ​ $ 294.16 Warrants issued ​ ​ 1,237,500 ​ ​ 1.55 ​ ​ (1,229,250) ​ ​ 59.60 ​ ​ 8,250 ​ ​ 60.00 Warrants exercised ​ ​ (1,456,453) ​ ​ 1.55 ​ ​ 1,446,743 ​ ​ 230.95 ​ ​ (9,710) ​ ​ 232.50 Warrants expired ​ ​ (3,000) ​ ​ 25.00 ​ ​ 2,980 ​ ​ 3,725.00 ​ ​ (20) ​ ​ 3,750.00 Warrants outstanding at September 30, 2023 ​ ​ 10,811,062 ​ $ 2.02 ​ ​ (10,738,989) ​ $ 272.88 ​ ​ 72,073 ​ $ 274.71 ​ On July 24, 2024, Company received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from July 3, 2024 to July 23, 2024, the closing bid price of the Company’s common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Basis of presentation. The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages. The Real Estate Entities own the land and hospital buildings, which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team. The population health management division includes our management services organization. Additionally, the population health management division owns and operates provider networks such as independent physician associations (“IPAs”). IPAs not owned by us are consolidated as VIEs because we are the primary beneficiary of these IPAs operations and have 100% control of these IPAs operations through management services agreements with each applicable IPA. All significant intercompany balances and transactions have been eliminated in consolidation. Interim financial statements. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2023 and 2022. Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates. Cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has cash amounts, that were at times material, held in covered banking institutions in excess of the insured amounts, but does not deem the risk of loss to be likely. The Company has $2.9 million in restricted cash as of September 30, 2024. The amounts included in restricted cash represent those required to be set aside either by note payable agreement or compensating balance requirements. Fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows: Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented. Segment reporting. A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments – the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities. Reclassifications . Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation. Recent accounting pronouncements. In November 2023, the FASB issued Accounting Standards Update 2023-07, “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025. In December 2023, the FASB issued Accounting Standards Update 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements.

Divestitures

Divestitures	9 Months Ended
	Sep. 30, 2024
Divestitures
Divestitures	Note 3 – Divestitures ​ Sale of Procare Health, Inc. impairment) for Procare was recorded for the three months ended September 30, 2024. The Company does not deem this transaction to be significant. ​ Sale of Clinigence Health, Inc. ​

Revenue

Revenue	9 Months Ended
	Sep. 30, 2024
Revenue
Revenue	Note 4 – Revenue ​ We disaggregate revenue from contracts with customers into types of services or products, consistent with our reportable segments, as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2024 2023 2024 2023 Hospital division revenue ​ ​ 71,732,529 ​ ​ 54,585,263 ​ ​ 199,366,776 ​ ​ 155,485,230 Population health management division revenue ​ ​ 7,062,340 ​ ​ 8,137,709 ​ ​ 22,964,141 ​ ​ 22,491,613 Total revenue ​ $ 78,794,869 ​ $ 62,722,972 ​ $ 222,330,917 ​ $ 177,976,843 ​ Hospital division revenue The following tables present the allocation of the estimated transaction price with the patient among the primary patient classification of insurance coverage: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Insurance ​ ​ 95% ​ ​ 92% ​ ​ 93% ​ ​ 93% Self pay ​ ​ 2% ​ ​ 5% ​ ​ 4% ​ ​ 4% Workers compensation ​ 2% ​ ​ 2% ​ 2% ​ ​ 2% Medicare/Medicaid ​ ​ 1% ​ ​ 1% ​ ​ 1% ​ ​ 1% Total ​ ​ 100% ​ ​ 100% ​ ​ 100% ​ ​ 100% ​ Population health management division revenue. selecting us as their healthcare provider. Capitation is a fixed payment amount per patient per unit of time paid in advance for the delivery of health care services, whereby the service providers are generally liable for excess medical costs. We receive management fees that are based on gross capitation revenues of the IPAs or physician groups we manage. Revenue is recognized and received monthly for our services.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2024
Property and Equipment
Property and Equipment	Note 5 - Property and Equipment ​ The principal categories of property and equipment, net are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Useful ​ September 30, ​ December 31, ​ Life (years) ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Buildings and improvements ​ 39 ​ $ 19,649,964 ​ $ 18,947,818 Land ​ - ​ 4,410,749 ​ 4,401,888 Leasehold improvements ​ 10-39 ​ 28,047,662 ​ 27,606,383 Construction in progress ​ - ​ 1,777,318 ​ 3,776,138 Medical equipment ​ 10 ​ 34,824,092 ​ 33,519,026 Office furniture and equipment ​ 7 ​ 3,973,548 ​ 3,698,874 Computer hardware and software ​ 5 ​ ​ 7,013,106 ​ ​ 6,066,520 Vehicles ​ 5 ​ 94,433 ​ 135,590 Signage ​ 10 ​ 2,060,535 ​ 1,576,475 Total cost ​ ​ ​ 101,851,407 ​ 99,728,712 Less: accumulated depreciation ​ ​ ​ (23,604,940) ​ ​ (18,341,063) Total property and equipment, net ​ ​ ​ $ 78,246,467 ​ $ 81,387,649 ​ ​ ​ ​ ​ We consolidate two Real Estate Entities in the Company. Refer to Note 18 ​ Depreciation and amortization of property and equipment for the three months ended September 30, 2024 and 2023 totaled $1.8 million and $1.6 million, respectively, and for the nine months ended September 30, 2024 and 2023 totaled $5.0 million and $4.0 million, respectively.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2024
Intangible Assets and Goodwill
Intangible Assets and Goodwill	Note 6 – Intangible Assets and Goodwill ​ Intangible Assets. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross ​ Accumulated ​ Net Carrying ​ Weighted Average September 30, 2024 ​ Carrying Amount ​ Amortization ​ Amount ​ Useful Life (in years) Amortizing intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Member relationships ​ $ 18,491,000 ​ $ 2,940,318 ​ $ 15,550,682 ​ ​ 15 Trademarks ​ ​ 474,000 ​ ​ 169,290 ​ ​ 304,710 ​ ​ 7 Total ​ $ 18,965,000 ​ $ 3,109,608 ​ $ 15,855,392 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortizing intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Member relationships ​ $ 18,491,000 ​ $ 2,015,772 ​ $ 16,475,228 ​ ​ 15 Management contracts ​ ​ 2,021,000 ​ ​ 221,047 ​ ​ 1,799,953 ​ ​ 16 Customer contracts ​ ​ 914,000 ​ ​ 106,633 ​ ​ 807,367 ​ ​ 15 Trademarks ​ ​ 1,426,795 ​ ​ 262,557 ​ ​ 1,164,238 ​ ​ 7-12 PHP technology ​ ​ 409,000 ​ ​ 143,150 ​ ​ 265,850 ​ ​ 5 Total ​ $ 23,261,795 ​ $ 2,749,159 ​ $ 20,512,636 ​ ​ ​ ​ Amortization of intangible assets for the three months ended September 30, 2024 and 2023 totaled $0.3 million and $0.4 million, respectively, and for the nine months ended September 30, 2024 and 2023 totaled $1.1 million and $1.2 million, respectively. Certain intangible assets were impaired upon the sale of Procare and sale of Clinigence Health, totaling $0.4 million and $3.9 million for three and nine months ended September 30, 2024, respectively. See Note 3 Goodwill. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital Division ​ Population Health Management Division ​ Total Balance as of December 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Goodwill ​ $ 1,139,297 ​ $ 415,201,301 ​ $ 416,340,598 Accumulated impairment losses ​ ​ (1,139,297) ​ ​ (398,135,038) ​ ​ (399,274,335) ​ ​ ​ - ​ ​ 17,066,263 ​ ​ 17,066,263 Purchase accounting adjustments ​ ​ - ​ ​ 502,864 ​ ​ 502,864 Impairment of goodwill ​ ​ - ​ ​ (3,197,391) ​ ​ (3,197,391) Derecognition of goodwill ​ ​ - ​ ​ (453,017) ​ ​ (453,017) Balance as of September 30, 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ Goodwill ​ ​ 1,139,297 ​ ​ 415,251,148 ​ ​ 416,390,445 Accumulated impairment losses ​ ​ (1,139,297) ​ ​ (401,332,429) ​ ​ (402,471,726) ​ ​ $ - ​ $ 13,918,719 ​ $ 13,918,719 ​ The purchase accounting adjustments of $0.5 million to the carrying amount of goodwill in the Population Health Management Division relates to the acquisition of two Florida based IPAs in the third quarter of 2023 for which the allocation of goodwill is subject to revision based on final allocation of the purchase price to the identifiable assets and liabilities acquired. ​ The impairment of goodwill of $3.2 million and the derecognition of goodwill of $0.5 million, both for the Population Health Management Division, relate to the sale of Procare Health, Inc., a wholly-owned subsidiary of Nutex. Procare was considered part of the Population Health Management Division. Prior to the sale of Procare, the Company recognized a goodwill impairment amount of $3.2 million. On the sale of Procare, the Company recognized the derecognition of goodwill of $0.5 million based on the remaining carrying amount of goodwill for the Procare business after impairment. See Note 3 ​ Due to the sale of Procare, the Company tested for impairment the remaining goodwill in the Population Health Management Division of $13.9 million. On June 30, 2024, we determined that the fair value of our Population Health Management Division was greater than its carrying value. Therefore, no goodwill impairment was recognized for the quarter ended June 30, 2024. No goodwill impairment recognized for the quarter ended and year ended September 30, 2024.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2024
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	Note 7 – Accrued Expenses and Other Current Liabilities ​ Accrued expenses and other current liabilities consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ Accrued wages and benefits ​ $ 12,279,378 ​ $ 6,590,710 Accrued supplier expenses ​ ​ 1,528,692 ​ ​ - Accrued medical insurance claims ​ ​ 4,023,293 ​ ​ 1,865,280 Accrued taxes ​ ​ 7,580,859 ​ ​ 405,352 Accrued other ​ 4,276,443 ​ ​ 4,093,954 Total accrued expenses and other current liabilities ​ $ 29,688,665 ​ $ 12,955,296 ​

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt
Debt	Note 8 – Debt ​ The Company’s outstanding debt is shown in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Maturity ​ Interest ​ September 30, ​ December 31, ​ Dates ​ Rates ​ 2024 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term loans secured by all assets 09/2024 - 09/2029 ​ 4.00 - 12.00% ​ $ 9,450,020 ​ $ 7,030,613 Term loans secured by property and equipment 10/2024 - 01/2030 ​ 3.41 - 7.82% ​ ​ 9,184,930 ​ ​ 10,562,207 Term loan secured by deposits 04/2025 ​ 7.36% ​ ​ 2,341,638 ​ ​ - Line of credit secured by all assets 01/2025 - 01/2026 ​ 7.75 - 9.50% ​ ​ 3,384,517 ​ ​ 3,371,675 Term loans of consolidated Real Estate Entities 05/2028 - 03/2037 ​ 3.50 - 3.59% ​ ​ 12,116,455 ​ ​ 13,005,019 Unsecured convertible term notes 10/2025 ​ 8.00 - 10.00% ​ ​ 5,384,990 ​ ​ 5,384,990 Pre-paid advance (convertible debt) 03/2024 ​ 0.00% ​ ​ - ​ ​ 3,078,302 Total ​ ​ ​ ​ ​ 41,862,550 ​ ​ 42,432,806 Less: unamortized issuance costs and discount ​ ​ ​ ​ ​ 1,176,690 ​ ​ 1,937,676 Less: short-term lines of credit ​ ​ ​ ​ ​ 3,384,517 ​ ​ 3,371,676 Less: current portion of long-term debt ​ ​ ​ ​ ​ 10,499,532 ​ ​ 10,808,721 Total long-term debt ​ ​ ​ ​ $ 26,801,811 ​ $ 26,314,733 ​ Term loans and lines of credit ​ Certain outstanding debt arrangements require minimum debt service coverage ratios and other financial covenants. At December 31, 2023, we were not in compliance with the debt service coverage ratio for one term loan with an outstanding balance of $0.3 million on December 31, 2023. As of September 30, 2024, we no longer had an outstanding balance on this loan. At September 30, 2024, we had remaining availability of $4.1 million under outstanding lines of credit. ​ Pre-Paid Advance Agreement (convertible debt). ​ On April 11, 2023, the Company entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd. (“Yorkville”) pursuant to which the Company requested an advance of $15.0 million from Yorkville a “Pre-Paid Advance”) purchased by Yorkville at 90% of the face amount. Interest accrued on the outstanding balance of the Pre-Paid Advance at an annual rate equal to 0% subject to an increase to 15% upon events of default described in the PPA. The Pre-Paid Advance has a maturity date of 12 months from the Pre-Paid Advance Date. ​ The Company, at its option, has the right, but not the obligation, to repay early in cash a portion or all amounts outstanding under any Pre-Paid Advance, provided that the VWAP of the Common Stock is less than the Fixed Price during a period of ten consecutive trading days immediately prior to the date on which the Company delivers a notice to Yorkville of its intent and such notice is delivered at least 10 ​ On April 11, 2023, the Company requested a $15.0 million initial Pre-Paid Advance in accordance with the PPA. The net proceeds of $13.5 million received by the Company from Yorkville reflect a 10% discount of $1.5 million in accordance with the PPA. Additionally, in connection with the PPA, the Company incurred $0.9 million in placement and legal fees, which the Company classifies as debt issuance costs. The discount and the debt issuance costs are reported as a direct deduction from the face amount of the PPA and are amortized monthly based on the effective interest rate method. The amortization of the discount and debt issuance costs are reported as interest expense in the condensed consolidated statements of operations. ​ As a result of the Pre-Paid Advance, the Company (i) issued 0.2 million shares of common stock to Yorkville (23.1 million prior to the 2024 Reverse Stock Splits), reducing the principal of initial Pre-Paid Advance to $7.3 million, (ii) made Optional Prepayments of $8.2 million in accordance with the PPA, consisting of $7.7 million of principal and $1.0 million attributed to the Payment Premium and (iii) paid off in full the remaining outstanding balance of the PPA on January 30, 2024 and the parties terminated the Yorkville PPA on February 15, 2024. ​ September 2023 Convertible Debt Issuance. ​ From September 2023 to December 2023, the Company conducted a private offering of convertible notes (“Unsecured Convertible Term Notes”) and six-year prior to the 2024 Reverse Stock Splits). We also issued Warrants for the purchase of ​ On March 26, 2024, the Company and the Holders agreed to amend the conversion price of the Unsecured Convertible Term Notes and exercise price of the Warrants to $30.00 each ($0.20 prior to the 2024 Reverse Stock Splits), resulting in the Unsecured Convertible Term Notes being convertible into 179,500 shares of common stock (26,925,000 prior to the 2024 Reverse Stock Splits), the Warrants exercisable for 89,750 shares of common stock (13,462,500 prior to the 2024 Reverse Stock Splits) and the placement agent Warrants exercisable for 53,850 shares of common stock (8,077,500 prior to the 2024 Reverse Stock Splits). ​ The Unsecured Convertible Term Notes bear an annual interest rate of 8% if paid in cash or an annual interest rate of 10% if paid in the form of common stock. The payment of interest in the form of common stock is at the discretion of the Company. When paid in common stock, the number of shares is equal to the quotient of the total accrued interest due divided by the last reported sale price of the Company’s common stock on the last complete trading day of such quarter. The Holders have the option, at any time, to convert all or any portion of the unpaid principal and interest outstanding in common stock at the conversion price of $30.00 per share. If the Company fails to pay the outstanding principal amount and all accrued interest within 30 days of the maturity date, the interest rate payable is adjusted to 12%. ​ The Company appointed Emerson Equity LLC as placement agent for the September 2023 Private Offering. Per the Placement Agent Agreement, the Company agrees to pay (i) a cash commission equal to 10% of the gross proceeds and (ii) warrants to purchase a number of Common Stock equal to 20% of the total number of shares issuable upon conversion or exercise of the Unsecured Convertible Term Notes and Warrants, as applicable. ​ The net carrying amount of the Unsecured Convertible Term Notes was $4.3 million as of September 30, 2024 and the weighted average effective interest rate on the convertible debt is 21.5%. The Unsecured Convertible Term Notes interest expense was $0.3 million for the three months ending September 30, 2024, comprising of $0.2 million in amortization expense and $0.1 million in accrued interest expense. For the nine months ended September 30, 2024 interest expense was $1.0 million, comprising of $0.7 million in amortization expense and $0.3 million in accrued interest expense. ​ ​ ​ ​ ​

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 9 – Leases ​ We have entered into hospital property, office and equipment rental agreements with various lessors including related parties. The following tables disclose information about our leases of property and equipment: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 228,162 ​ $ 789,877 ​ $ 1,442,082 ​ $ 2,676,894 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ 2,912,084 ​ $ 2,858,223 ​ $ 7,591,105 ​ $ 7,889,533 Interest on lease liabilities ​ ​ 4,516,634 ​ ​ 3,203,802 ​ ​ 12,033,035 ​ ​ 8,718,643 Total finance lease cost ​ $ 7,428,718 ​ $ 6,062,025 ​ $ 19,624,140 ​ $ 16,608,176 ​

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies
Commitments and Contingencies	Note 10 – Commitments and Contingencies ​ Litigation

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2024
Stock-based Compensation
Stock-based Compensation	Note 11 – Stock-based Compensation ​ In 2023, the stockholders of the Company approved the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan (the “2023 Plan”), providing a total of 73,426 shares of Common Stock (11,013,943 prior to the 2024 Reverse Stock Splits) for issuance. Awards granted under the 2023 Plan may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant. The 2023 Plan is subject to annual increases on January 1st of each calendar year through January 1, 2033 of up to 1% of the issued and outstanding shares of the Company’s Common Stock on the final day of the preceding calendar year, at the discretion of the Compensation Committee of our Board of Directors. During the second quarter of 2024, the number of shares to be issued under the 2023 Plan increased to 118,563 shares, most of which were issued as restricted stock units in June 2024, as discussed below. ​ Obligations for under-construction and ramping hospitals. ​ ● With respect to ramping hospitals that were acquired before the Merger, 24 months after the opening date (the “Determination Date”) of the applicable ramping hospital, such owner is eligible to receive such owner’s pro rata share of a number of shares of Company Common Stock equal to (i) the trailing twelve months earnings before interest, taxes, depreciation and amortization on the respective Determination Date, multiplied by (ii) 10 , (iii) minus the initial equity value received at the Closing of the Merger, and (iv) minus such owner’s pro rata share of the aggregate debt of the applicable ramping hospital outstanding as of the closing of the Merger. The number of additional shares to be issued will be determined based on the greater of (a) the price of the Company’s common stock at the time of determination or (b) $2.80 ( $420.00 after the 2024 Reverse Stock Splits), as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to the Company’s common stock. ​ ● With respect to under construction hospitals that were acquired before the Merger, contributing owners of under construction hospitals will be eligible to receive, on the Determination Date, such owner’s pro rata share of a number of shares of Company common stock equal to (a)(i) the trailing twelve months earnings before interest, taxes, depreciation and amortization as of the Determination Date multiplied by (ii) 10 , minus (iii) the aggregate amount of such owner’s capital contribution to the under construction hospital, minus (iv) such owner’s pro rata share of the aggregate debt of the applicable under construction hospital outstanding as of the Closing of the Merger, divided by (b) the greater of (i) the price of the Company common stock at the time of determination or (ii) $2.80 ( $420.00 after the 2024 Reverse Stock Splits), as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to the Company’s common stock. ​ We recognized stock-based compensation expense related to obligations for under-construction and ramping hospitals for three and nine months ended September 30, 2024 of $1.9 million and $1.7 million, respectively, based on our current estimates of future obligations to the contributing owners. ​ Options ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ Options ​ Weighted Average ​ Remaining Contractual ​ ​ Outstanding ​ Exercise Price ​ Life (Years) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding at December 31, 2022 ​ ​ 34,318 ​ $ 345.00 ​ ​ 7.60 Options exercised ​ ​ — ​ ​ — ​ ​ ​ Options cancelled ​ ​ — ​ ​ — ​ ​ ​ Options outstanding at September 30, 2023 ​ ​ 34,318 ​ $ 345.00 ​ ​ 6.85 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding at December 31, 2023 ​ ​ 27,590 ​ $ 335.75 ​ ​ 6.94 Options exercised ​ ​ — ​ ​ — ​ ​ ​ Options cancelled ​ ​ (3,334) ​ ​ 367.51 ​ ​ ​ Options outstanding at September 30, 2024 ​ ​ 24,256 ​ $ 335.75 ​ ​ 5.68 ​ Options outstanding as of September 30, 2024 consisted of: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expiration ​ Number ​ Number ​ Exercise Date ​ Outstanding ​ Exercisable ​ Price ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 21, 2025 ​ ​ 686 ​ ​ 686 ​ $ 225.00 January 21, 2025 ​ ​ 300 ​ ​ 300 ​ ​ 241.50 January 21, 2025 ​ ​ 1,214 ​ ​ 1,214 ​ ​ 412.50 January 27, 2027 ​ ​ 300 ​ ​ 300 ​ ​ 225.00 May 11, 2027 ​ ​ 1,401 ​ ​ 1,401 ​ ​ 225.00 June 9, 2027 ​ ​ 167 ​ ​ 167 ​ ​ 376.50 January 28, 2028 ​ ​ 300 ​ ​ 300 ​ ​ 241.50 August 4, 2029 ​ ​ 68 ​ ​ 68 ​ ​ 834.00 January 27, 2030 ​ ​ 1,157 ​ ​ 1,157 ​ ​ 225.00 June 30, 2030 ​ ​ 715 ​ ​ 715 ​ ​ 217.50 January 28, 2031 ​ ​ 6,667 ​ ​ 6,667 ​ ​ 241.50 September 9, 2031 ​ ​ 10,780 ​ ​ 10,780 ​ ​ 412.50 December 17, 2031 ​ ​ 501 ​ ​ 501 ​ ​ 525.00 Total ​ ​ 24,256 ​ ​ 24,256 ​ ​ ​ ​ Restricted Stock Units ​ On June 16, 2024, the Company issued 118,538 RSUs (1,184,946 prior to the 1 ​ For grants of restricted stock units, we recognize compensation expense over the applicable vesting period equal to the fair value of our common stock at grant date. Grants of restricted stock units generally vest one ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares (in thousands) Weighted Average Grant-Date Fair Value Per Share ​ ​ ​ ​ ​ ​ ​ Non-vested awards, December 31, 2022 ​ ​ — ​ ​ — Granted ​ ​ 4 ​ $ 151.50 Vested ​ (1) ​ ​ 151.50 Non-vested awards, September 30, 2023 ​ ​ 3 ​ $ 151.50 ​ ​ ​ ​ ​ ​ ​ Non-vested awards, December 31, 2023 ​ ​ 3 ​ $ 151.50 Granted ​ ​ 118 ​ ​ 5.40 Forfeitures ​ ​ (3) ​ ​ 92.48 Vested ​ ​ (1) ​ ​ 151.50 Non-vested awards, September 30, 2024 ​ ​ 117 ​ $ 37.23 ​ As of September 30, 2024, we estimate $0.7 million of unrecognized compensation cost related to restricted stock units issued to our employees to be recognized over the weighted-average vesting period of 1.7 years. ​ Employee Stock Purchase Plan

Equity

Equity	9 Months Ended
	Sep. 30, 2024
Equity
Equity	Note 12 – Equity ​ We are authorized to issue up to a total of 950,000,000 shares of common stock having a par value of $0.001 per share. Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and to receive ratably in proportion to the shares of common stock held by them any dividends declared from time to time by the board of directors. Our common stock has no preferences or rights of conversion, exchange, pre-exemption or other subscription rights. ​ Common Stock Issued ​ Securities Purchase Agreement. ​ On January 22, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare focused institutional investor for the sale by the Company of 444,445 shares (66,666,666 prior to the 2024 Reverse Stock Splits) of the Company’s common stock, par value $0.001 per share, and warrants (the “Warrants”) to purchase 444,445 shares (66,666,666 prior to the 2024 Reverse Stock Splits) of the Company’s common stock. The shares and the warrants were issued separately and issued on a one-to-one ratio at a public offering price of $22.50 per share and accompanying warrant ($0.15 prior to the 2024 Reverse Stock Splits). ​ The Warrants have an exercise price of $22.50 per share ($0.15 prior to the 2024 Reverse Stock Splits), are exercisable immediately upon issuance and expire five years from the Closing Date. The Warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained therein is not available for, the issuance or resale of shares of common stock underlying the Warrants to or by the holder. The holder of a Warrant is prohibited from exercising any such warrants to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 4.99% (or, upon election by the holder prior to the issuance of any Warrants, 9.99%) of the total number of shares of common stock outstanding immediately after giving effect to the exercise. In the event of certain fundamental transactions, the holder of the Warrants will have the right to receive the Black Scholes Value of its Warrants calculated pursuant to a formula set forth in the Form of Warrant, payable either in cash or in the same type or form of consideration that is being offered and being paid to the holders of common stock. ​ The gross proceeds to the Company from the offering were $9.2 million after deducting the placement agent’s fees and other offering expenses of $0.8 million. The allocation of the proceeds was $7.7 million to warrant liability and $1.5 million to additional paid-in capital. ​ The Company used the Black-Scholes option model to compute the fair value (level 3) of the Warrants, with inputs including volatility (approximately 120%) and risk-free rate based on US Treasury yield curve rates. The Company classified the Warrants as liabilities due to certain contractual provisions and recorded $7.7 million in warrant liability on January 25, 2024. 150,000 Warrants were exercised in the third quarter of 2024 and the Company received $0.8 million in proceeds for Warrant exercises. For each exercise, the Company remeasured the Warrants based on the exercise date, recognized a gain or loss on warrant liability, and allocated the exercised portion of the warrant liability to additional paid-in capital. The Company remeasured the Warrants on September 30, 2024, recognizing the fair value of the warrant liability of $5.7 million at September 30, 2024. For the three and nine months ended September 30, 2024, the Company recognized $6.7 million and $1.1 million loss on warrant liability, respectively. ​ Under the Purchase Agreement, if the Company, at any time while the Warrants are outstanding, combines (including by way of reverse share split) outstanding shares of common stock into a smaller number, then, on the tenth trading day following, the exercise price will be reduced, and only reduced, to the lesser of (i) the then exercise price and (ii) 100% of the average of the volume weighted average prices for the ten trading day period immediately following. On April 26, 2024, as required under the terms of the Purchase Agreement in response to the 1 1 ​ Warrants. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ Warrants ​ Weighted Average ​ Remaining Contractual ​ ​ Outstanding ​ Exercise Price ​ Life (years) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding at December 31, 2022 ​ ​ 73,553 ​ $ 294.16 ​ ​ 3.80 Warrants issued ​ ​ 8,250 ​ ​ 60.00 ​ ​ ​ Warrants exercised ​ ​ (9,710) ​ ​ 232.50 ​ ​ ​ Warrants expired ​ ​ (20) ​ ​ 3,750.00 ​ ​ ​ Warrants outstanding at September 30, 2023 ​ ​ 72,073 ​ $ 274.71 ​ ​ 3.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding at December 31, 2023 ​ ​ 135,537 ​ $ 158.16 ​ ​ 4.42 Warrants issued ​ ​ 444,445 ​ ​ 6.80 ​ ​ ​ Warrants amended ​ ​ 71,801 ​ ​ 30.00 ​ ​ ​ Warrants exercised ​ ​ (150,000) ​ ​ 5.34 ​ ​ ​ Warrants outstanding at September 30, 2024 ​ ​ 501,783 ​ $ 50.15 ​ ​ 4.56 ​ Warrants outstanding as of September 30, 2024 consisted of: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expiration ​ Number ​ Number ​ Exercise Date ​ Outstanding ​ Exercisable ​ Price ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2024 ​ ​ 3,701 ​ ​ 3,701 ​ $ 1,000.50 October 31, 2025 ​ ​ 108 ​ ​ 108 ​ ​ 187.50 October 31, 2025 ​ ​ 10,444 ​ ​ 10,444 ​ ​ 232.50 February 26, 2026 ​ ​ 1,922 ​ ​ 1,922 ​ ​ 600.00 July 31, 2026 ​ ​ 16,888 ​ ​ 16,888 ​ ​ 232.50 May 31, 2027 ​ ​ 30,674 ​ ​ 30,674 ​ ​ 262.50 September 30, 2029 ​ ​ 294,445 ​ ​ 294,445 ​ ​ 5.34 October 31, 2029 ​ ​ 16,501 ​ ​ 16,501 ​ ​ 30.00 November 30, 2029 ​ ​ 57,250 ​ ​ 57,250 ​ ​ 30.00 December 31, 2029 ​ ​ 5,167 ​ ​ 5,167 ​ ​ 30.00 January 25, 2029 ​ ​ 64,683 ​ ​ 64,683 ​ ​ 30.00 Total ​ ​ 501,783 ​ ​ 501,783 ​ ​ ​ ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes
Income Taxes	Note 13 – Income Taxes ​ Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. The income tax impact of discrete items is recognized in the period these occur. Our effective tax rate for the three and nine months ended September 30, 2024 was (177.7)% and 501.2%, respectively. The primary difference from the federal statutory rate of 21% is related to state taxes, income of noncontrolling interests in flow-through entities and permanent differences for non-deductible expenses.

Earnings per Share

Earnings per Share	9 Months Ended
	Sep. 30, 2024
Earnings per Share
Earnings per Share	Note 14 – Earnings per Share The following is the computation of loss per basic and diluted share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 Amounts attributable to Nutex Health Inc.: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss attributable to common stockholders ​ $ (8,788,313) ​ $ (5,542,391) ​ $ (9,516,436) ​ $ (14,168,717) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares used to compute basic EPS ​ ​ 5,100,030 ​ ​ 4,433,704 ​ ​ 4,973,463 ​ ​ 4,383,935 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ (1.72) ​ $ (1.25) ​ $ (1.91) ​ $ (3.23) Diluted ​ $ (1.72) ​ $ (1.25) ​ $ (1.91) ​ $ (3.23) ​ Due to antidilution, the computation of diluted earnings per common share excludes the 24,256 common stock options ( 3,638,355 prior to the 2024 Reverse Stock Splits), 501,783 warrants ( 75,267,450 prior to the 2024 Reverse Stock Splits), 1,298 restricted stock units ( 194,720 prior to the 2024 Reverse Stock Splits) and 179,500 common stock ( 26,925,000 prior to the 2024 Reverse Stock Splits) issuable upon conversion of outstanding convertible debt for the three and nine months ended September 30, 2024. Due to antidilution, the September 30, 2023 computation excludes the 34,318 common stock options ( 5,147,770 prior to the 2024 Reverse Stock Splits) and 72,074 warrants ( 10,811,062 prior to the 2024 Reverse Stock Splits). The dilutive effect of convertible debt was calculated using the if-converted method, whereas the dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method.

Supplemental Cash Flows Informa

Supplemental Cash Flows Information	9 Months Ended
	Sep. 30, 2024
Supplemental Cash Flows Information
Supplemental Cash Flows Information	Note 15 - Supplemental Cash Flows Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2024 2023 Cash paid for interest ​ $ 2,459,932 ​ $ 858,773 Cash paid for income taxes ​ ​ 1,552,000 ​ ​ 737,000 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ Financed capital expenditures ​ ​ 1,039,126 ​ ​ 5,521,759 Acquisition of finance leases ​ ​ 15,628,963 ​ ​ 18,798,667 Exercise of warrants on cashless basis ​ ​ - ​ ​ 1,268 Issuance of restricted stock units ​ ​ - ​ ​ 298,812 Issuance of common stock to Apollo Medical Holdings, Inc. ​ ​ - ​ ​ 1,900,000 Deconsolidation of Real Estate Entity ​ ​ - ​ ​ 4,258,133 Warrant liability related to common stock issuance ​ ​ 7,661,557 ​ ​ - Reverse stock split adjustment ​ ​ 3 ​ ​ - Common stock issued for Employee Stock Purchase Plan ​ ​ 58,805 ​ ​ - Convertible debt converted to common stock ​ ​ 320,688 ​ ​ 5,151,509 Warrants issued with convertible debt ​ ​ - ​ ​ 175,710 Payment for acquisition in common stock ​ ​ 406,158 ​ ​ 750,000 Common stock received in sale of business ​ ​ 30,250 ​ ​ - ​

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2024
Segment Information
Segment Information	Note 16 – Segment Information ​ We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (ii) the real estate division. The determination of our reporting segments was made on the basis of our strategic priorities, which corresponds to the manner in which our Chief Executive Officer, as our chief operating decision maker, reviews and evaluates operating performance to make decisions about resources to be allocated. We evaluate the performance of our reportable segments based on, among other measures, operating income, which is defined as income before interest expense, other income (expense), and taxes. Corporate costs primarily include expenses for support functions and salaries and benefits for corporate employees and are excluded from segment operating results. ​ Reportable segment information, including intercompany transactions, is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2024 ​ 2023 Assets: ​ ​ ​ ​ ​ ​ Hospital division ​ $ 387,114,599 ​ $ 278,635,841 Population health management division ​ ​ 31,958,362 ​ ​ 83,647,378 Real estate division ​ ​ 19,415,643 ​ ​ 35,962,278 Total Assets ​ $ 438,488,604 ​ $ 398,245,497 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 Revenue from external customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ $ 71,732,529 ​ $ 54,585,263 ​ $ 199,366,776 ​ $ 155,485,230 Population health management division ​ ​ 7,062,340 ​ ​ 8,137,709 ​ ​ 22,964,141 ​ ​ 22,491,613 Total revenue ​ $ 78,794,869 ​ $ 62,722,972 ​ $ 222,330,917 ​ $ 177,976,843 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Segment operating income (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ ​ 21,437,835 ​ ​ 7,238,738 ​ ​ 54,700,084 ​ ​ 21,122,489 Population health management division ​ ​ 478,979 ​ ​ (172,525) ​ ​ (64,861) ​ ​ 438,370 Total segment operating income ​ $ 21,916,814 ​ $ 7,066,213 ​ $ 54,635,223 ​ $ 21,560,859 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ ​ 617,159 ​ ​ 2,875,585 ​ ​ 1,908,651 ​ ​ 10,322,487 Real estate division ​ ​ - ​ ​ - ​ ​ - ​ ​ - Total capital expenditures ​ $ 617,159 ​ $ 2,875,585 ​ $ 1,908,651 ​ $ 10,322,487 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue from inter-segment activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Real estate division ​ $ - ​ $ 13,192,549 ​ $ 603,255 ​ $ 13,708,579 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ ​ 4,514,723 ​ ​ 4,238,498 ​ ​ 11,949,282 ​ ​ 11,518,388 Population health management division ​ ​ 360,395 ​ ​ 401,566 ​ ​ 1,192,695 ​ ​ 1,201,227 Real estate division ​ ​ 97,360 ​ ​ 105,877 ​ ​ 549,507 ​ ​ 189,233 Total depreciation and amortization ​ $ 4,972,478 ​ $ 4,745,941 ​ $ 13,691,484 ​ $ 12,908,848 ​

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions
Related Party Transactions	Note 17 – Related Party Transactions ​ Related party transactions included the following: ​ ● The Physician LLCs employ the doctors who work in our hospitals. We have no direct ownership interest in these entities, but they are owned and, in some instances, controlled by related parties including our CEO, Dr. Thomas Vo. The Physician LLCs are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to them in the event of cash shortages and received the benefit of their cash surpluses. ​ The Physician LLCs had outstanding obligations to their member owners, who are also Company stockholders. These outstanding obligations primarily represent contributions for facilities currently under construction totaling $3.5 million at September 30, 2024 and $2.9 million at December 31, 2023 reported within accounts payable – related party in our consolidated balance sheets. ​ ● Most of our hospital division facilities are leased from real estate entities which are owned by related parties. These leases are typically on a triple net basis, where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Our obligations under these leases are presented in Note 9 . During the three and nine months ended September 30, 2024, we made cash payments for these lease obligations totaling $5.1 million and $14.7 million, respectively. Cash payments for these lease obligations made in the three and nine months ended September 30, 2023 totaled $3.9 million and $11.1 million, respectively. ​ ● We consolidate Real Estate Entities as VIEs when they do not have sufficient equity at risk and our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We have no direct ownership interest in these entities, but they are owned and, in some instances, controlled by related parties including our CEO. We deconsolidated 17 Real Estate Entities in the second quarter of 2022 and one Real Estate Entity in the first quarter of 2023. As of September 30, 2024, two Real Estate Entities continue to be consolidated in our financial statements. ​ ● Accounts receivable – related party included $3.6 million at September 30, 2024 and $4.1 million at December 31, 2023 due from noncontrolling interest owners of consolidated ER Entities. ​ ● Micro Hospital Holding LLC, an affiliate controlled by our CEO, and 2GT PLLC, an affiliate controlled by a physician partner, made advances to one of our hospital facilities, SE Texas ER. These advances totaled $1.4 million for Micro Hospital Holding LLC and $1.2 million for 2GT PLLC at September 30, 2024 and December 31, 2023 and are reported as accounts payable – related party in our consolidated balance sheets. The advances have no stated maturity and bear no interest. ​ ● Accounts payable – related party in our consolidated balance sheets included $0.2 million at September 30, 2024 and $0.9 million at December 31, 2023 for reimbursement of expenses incurred on our behalf. ​ ● We provided managerial services to emergency centers owned and, in some instances, controlled by related parties including an entity controlled by our CEO during 2023. In the three and nine months ended September 30, 2023, we recognized $0.1 million and $0.5 million, respectively, of revenue for these services. ​ ● Two of our ER Entities were obligated under managerial services agreements with related parties commencing in 2022 and ending in 2023. Payments under these agreements totaled $0.1 million and $0.5 million for the three and nine months ended September 30, 2023. ​

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2024
Variable Interest Entities
Variable Interest Entities	Note 18 – Variable Interest Entities ​ The following tables provide the balance sheet amounts for consolidated VIEs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2024 ​ Real Estate ​ Physician ​ AHISP ​ Entities ​ LLCs ​ IPA ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets $ 37,348 ​ $ 8,274,490 ​ $ 13,446,657 Property and equipment, net ​ - ​ ​ 3,668 ​ ​ 100,868 Long-term assets ​ 33,181,530 ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets $ 33,218,878 ​ $ 8,278,158 ​ $ 13,547,525 ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities ​ - ​ ​ 5,019,463 ​ ​ 13,547,525 Long-term liabilities ​ 12,073,186 ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities ​ 12,073,186 ​ ​ 5,019,463 ​ ​ 13,547,525 ​ ​ ​ ​ ​ ​ ​ ​ ​ Equity ​ 21,145,692 ​ ​ 3,258,695 ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities and equity $ 33,218,878 ​ $ 8,278,158 ​ $ 13,547,525 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ Real Estate ​ Physician ​ AHISP ​ Entities ​ LLCs ​ IPA ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets $ 138,342 ​ $ 8,074,928 ​ $ 8,473,486 Property and equipment, net ​ - ​ ​ 3,668 ​ ​ 65,277 Long-term assets ​ 33,089,636 ​ ​ - ​ ​ 36,452 ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets $ 33,227,978 ​ $ 8,078,596 ​ $ 8,575,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities ​ 38,510 ​ ​ 5,648,516 ​ ​ 8,575,215 Long-term liabilities ​ 12,959,171 ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities ​ 12,997,681 ​ ​ 5,648,516 ​ ​ 8,575,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ Equity ​ 20,230,297 ​ ​ 2,430,080 ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities and equity $ 33,227,978 ​ $ 8,078,596 ​ $ 8,575,215 ​ The assets of each of the ER Entities may only be used to settle the liabilities of that entity or its consolidated VIEs and may not be required to be used to settle the liabilities of any of the other ER Entities, other VIEs, or corporate entity. Additionally, the assets of corporate entities cannot be used to settle the liabilities of VIEs. The Company has aggregated all of the Physician LLCs and Real Estate Entities into two categories above, because they have similar risk characteristics, and presenting distinct financial information for each VIE would not add more useful information. ​ Real Estate Entities are consolidated by the Company as VIEs because they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. As of September 30, 2024, two Real Estate Entities continue to be consolidated in our financial statements. ​ The Real Estate Entity we deconsolidated in the first quarter of 2023 had $1.0 million of cash, $8.4 million of fixed assets (principally land and building), $0.2 million of other assets, $5.4 million of liabilities (principally mortgage indebtedness) and $4.3 million of equity reported as noncontrolling interests as of the date of deconsolidation.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events
Subsequent Events	Note 19 - Subsequent Events ​ The Company has evaluated subsequent events through the filing of this report and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements, except the following: ​ Common stock issued. Subsequent to September 30, 2024, the Company issued 219,996 common shares for gross proceeds totaling $1.2 million from the exercise of warrants, as of the date of this Report. ​ * * * * *

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (8,788,313)	$ (5,542,391)	$ (9,516,436)	$ (14,168,717)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies
Basis of presentation	Basis of presentation. The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages. The Real Estate Entities own the land and hospital buildings, which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team. The population health management division includes our management services organization. Additionally, the population health management division owns and operates provider networks such as independent physician associations (“IPAs”). IPAs not owned by us are consolidated as VIEs because we are the primary beneficiary of these IPAs operations and have 100% control of these IPAs operations through management services agreements with each applicable IPA. All significant intercompany balances and transactions have been eliminated in consolidation.
Interim financial statements	Interim financial statements. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2023 and 2022.
Use of estimates	Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has cash amounts, that were at times material, held in covered banking institutions in excess of the insured amounts, but does not deem the risk of loss to be likely. The Company has $2.9 million in restricted cash as of September 30, 2024. The amounts included in restricted cash represent those required to be set aside either by note payable agreement or compensating balance requirements.
Fair value measurements	Fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows: Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented.
Segment reporting	Segment reporting. A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments – the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities.
Reclassifications	Reclassifications . Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation.
Recent accounting pronouncements	Recent accounting pronouncements. In November 2023, the FASB issued Accounting Standards Update 2023-07, “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025. In December 2023, the FASB issued Accounting Standards Update 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements.

Organization and Operations (Ta

Organization and Operations (Tables)	9 Months Ended
	Sep. 30, 2024
Organization and Operations
Schedule of reverse stock splits retroactively adjusted for the periods	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common Stock - Shares ​ ​ 670,711,741 ​ ​ (666,240,330) ​ ​ 4,471,411 Common Stock - Amount ​ $ 670,712 ​ $ (666,240) ​ $ 4,472 Additional Paid-in Capital ​ $ 466,711,720 ​ $ 666,240 ​ $ 467,377,960 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common Stock - Shares ​ ​ 676,679,911 ​ ​ (672,168,712) ​ ​ 4,511,199 Common Stock - Amount ​ $ 676,680 ​ $ (672,169) ​ $ 4,511 Additional Paid-in Capital ​ $ 469,849,049 ​ $ 672,169 ​ $ 470,521,218 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common Stock - Shares ​ ​ 650,223,840 ​ ​ (645,889,014) ​ ​ 4,334,826 Common Stock - Amount ​ $ 650,224 ​ $ (645,889) ​ $ 4,335 Additional Paid-in Capital ​ $ 458,498,402 ​ $ 645,889 ​ $ 459,144,291 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Loss attributable to common stockholders ​ $ (5,542,391) ​ $ - ​ $ (5,542,391) Weighted average shares used to compute basic and diluted EPS ​ ​ 665,055,603 ​ ​ (660,621,899) ​ ​ 4,433,704 Loss per share - basic and diluted ​ $ (0.01) ​ $ (1.23) ​ $ (1.25) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Loss attributable to common stockholders ​ $ (14,168,717) ​ $ - ​ $ (14,168,717) Weighted average shares used to compute basic and diluted EPS ​ ​ 657,590,265 ​ ​ (653,206,330) ​ ​ 4,383,935 Loss per share - basic and diluted ​ $ (0.01) ​ $ (3.22) ​ $ (3.23) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three and nine months ended September 30, 2023 ​ ​ ​ As Previously ​ ​ Impact of 2024 Reverse ​ ​ As ​ ​ ​ Reported ​ ​ Stock Splits ​ ​ Revised Common stock options ​ ​ 5,147,770 ​ ​ (5,113,452) ​ ​ 34,318 Common stock warrants ​ ​ 10,811,062 ​ ​ (10,738,988) ​ ​ 72,074 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Previously Reported ​ Impact of the 2024 Reverse Stock Splits ​ Revised ​ ​ Options ​ Weighted Average ​ Options ​ Weighted Average ​ Options ​ Weighted Average ​ ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price Options outstanding at December 31, 2022 ​ ​ 5,147,770 ​ $ 2.30 ​ ​ (5,113,452) ​ $ 342.70 ​ ​ 34,318 ​ $ 345.00 Options exercised ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Options cancelled ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Options outstanding at September 30, 2023 ​ ​ 5,147,770 ​ $ 2.30 ​ ​ (5,113,452) ​ $ 342.70 ​ ​ 34,318 ​ $ 345.00 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Previously Reported ​ Impact of the 2024 Reverse Stock Splits ​ Revised ​ ​ Warrants ​ Weighted Average ​ Warrants ​ Weighted Average ​ Warrants ​ Weighted Average ​ ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price ​ Outstanding ​ Exercise Price Warrants outstanding at December 31, 2022 ​ ​ 11,033,015 ​ $ 1.96 ​ ​ (10,959,462) ​ $ 292.20 ​ ​ 73,553 ​ $ 294.16 Warrants issued ​ ​ 1,237,500 ​ ​ 1.55 ​ ​ (1,229,250) ​ ​ 59.60 ​ ​ 8,250 ​ ​ 60.00 Warrants exercised ​ ​ (1,456,453) ​ ​ 1.55 ​ ​ 1,446,743 ​ ​ 230.95 ​ ​ (9,710) ​ ​ 232.50 Warrants expired ​ ​ (3,000) ​ ​ 25.00 ​ ​ 2,980 ​ ​ 3,725.00 ​ ​ (20) ​ ​ 3,750.00 Warrants outstanding at September 30, 2023 ​ ​ 10,811,062 ​ $ 2.02 ​ ​ (10,738,989) ​ $ 272.88 ​ ​ 72,073 ​ $ 274.71

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue
Schedule of disaggregate revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2024 2023 2024 2023 Hospital division revenue ​ ​ 71,732,529 ​ ​ 54,585,263 ​ ​ 199,366,776 ​ ​ 155,485,230 Population health management division revenue ​ ​ 7,062,340 ​ ​ 8,137,709 ​ ​ 22,964,141 ​ ​ 22,491,613 Total revenue ​ $ 78,794,869 ​ $ 62,722,972 ​ $ 222,330,917 ​ $ 177,976,843
Schedule of allocation of the estimated transaction price	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Insurance ​ ​ 95% ​ ​ 92% ​ ​ 93% ​ ​ 93% Self pay ​ ​ 2% ​ ​ 5% ​ ​ 4% ​ ​ 4% Workers compensation ​ 2% ​ ​ 2% ​ 2% ​ ​ 2% Medicare/Medicaid ​ ​ 1% ​ ​ 1% ​ ​ 1% ​ ​ 1% Total ​ ​ 100% ​ ​ 100% ​ ​ 100% ​ ​ 100%

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property and Equipment
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Useful ​ September 30, ​ December 31, ​ Life (years) ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Buildings and improvements ​ 39 ​ $ 19,649,964 ​ $ 18,947,818 Land ​ - ​ 4,410,749 ​ 4,401,888 Leasehold improvements ​ 10-39 ​ 28,047,662 ​ 27,606,383 Construction in progress ​ - ​ 1,777,318 ​ 3,776,138 Medical equipment ​ 10 ​ 34,824,092 ​ 33,519,026 Office furniture and equipment ​ 7 ​ 3,973,548 ​ 3,698,874 Computer hardware and software ​ 5 ​ ​ 7,013,106 ​ ​ 6,066,520 Vehicles ​ 5 ​ 94,433 ​ 135,590 Signage ​ 10 ​ 2,060,535 ​ 1,576,475 Total cost ​ ​ ​ 101,851,407 ​ 99,728,712 Less: accumulated depreciation ​ ​ ​ (23,604,940) ​ ​ (18,341,063) Total property and equipment, net ​ ​ ​ $ 78,246,467 ​ $ 81,387,649

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2024
Intangible Assets and Goodwill
Schedule of detail of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross ​ Accumulated ​ Net Carrying ​ Weighted Average September 30, 2024 ​ Carrying Amount ​ Amortization ​ Amount ​ Useful Life (in years) Amortizing intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Member relationships ​ $ 18,491,000 ​ $ 2,940,318 ​ $ 15,550,682 ​ ​ 15 Trademarks ​ ​ 474,000 ​ ​ 169,290 ​ ​ 304,710 ​ ​ 7 Total ​ $ 18,965,000 ​ $ 3,109,608 ​ $ 15,855,392 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortizing intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Member relationships ​ $ 18,491,000 ​ $ 2,015,772 ​ $ 16,475,228 ​ ​ 15 Management contracts ​ ​ 2,021,000 ​ ​ 221,047 ​ ​ 1,799,953 ​ ​ 16 Customer contracts ​ ​ 914,000 ​ ​ 106,633 ​ ​ 807,367 ​ ​ 15 Trademarks ​ ​ 1,426,795 ​ ​ 262,557 ​ ​ 1,164,238 ​ ​ 7-12 PHP technology ​ ​ 409,000 ​ ​ 143,150 ​ ​ 265,850 ​ ​ 5 Total ​ $ 23,261,795 ​ $ 2,749,159 ​ $ 20,512,636 ​ ​ ​
Schedule of carrying amount of goodwill, by operating segment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital Division ​ Population Health Management Division ​ Total Balance as of December 31, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ Goodwill ​ $ 1,139,297 ​ $ 415,201,301 ​ $ 416,340,598 Accumulated impairment losses ​ ​ (1,139,297) ​ ​ (398,135,038) ​ ​ (399,274,335) ​ ​ ​ - ​ ​ 17,066,263 ​ ​ 17,066,263 Purchase accounting adjustments ​ ​ - ​ ​ 502,864 ​ ​ 502,864 Impairment of goodwill ​ ​ - ​ ​ (3,197,391) ​ ​ (3,197,391) Derecognition of goodwill ​ ​ - ​ ​ (453,017) ​ ​ (453,017) Balance as of September 30, 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ Goodwill ​ ​ 1,139,297 ​ ​ 415,251,148 ​ ​ 416,390,445 Accumulated impairment losses ​ ​ (1,139,297) ​ ​ (401,332,429) ​ ​ (402,471,726) ​ ​ $ - ​ $ 13,918,719 ​ $ 13,918,719

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ Accrued wages and benefits ​ $ 12,279,378 ​ $ 6,590,710 Accrued supplier expenses ​ ​ 1,528,692 ​ ​ - Accrued medical insurance claims ​ ​ 4,023,293 ​ ​ 1,865,280 Accrued taxes ​ ​ 7,580,859 ​ ​ 405,352 Accrued other ​ 4,276,443 ​ ​ 4,093,954 Total accrued expenses and other current liabilities ​ $ 29,688,665 ​ $ 12,955,296 ​

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt
Schedule of debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Maturity ​ Interest ​ September 30, ​ December 31, ​ Dates ​ Rates ​ 2024 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term loans secured by all assets 09/2024 - 09/2029 ​ 4.00 - 12.00% ​ $ 9,450,020 ​ $ 7,030,613 Term loans secured by property and equipment 10/2024 - 01/2030 ​ 3.41 - 7.82% ​ ​ 9,184,930 ​ ​ 10,562,207 Term loan secured by deposits 04/2025 ​ 7.36% ​ ​ 2,341,638 ​ ​ - Line of credit secured by all assets 01/2025 - 01/2026 ​ 7.75 - 9.50% ​ ​ 3,384,517 ​ ​ 3,371,675 Term loans of consolidated Real Estate Entities 05/2028 - 03/2037 ​ 3.50 - 3.59% ​ ​ 12,116,455 ​ ​ 13,005,019 Unsecured convertible term notes 10/2025 ​ 8.00 - 10.00% ​ ​ 5,384,990 ​ ​ 5,384,990 Pre-paid advance (convertible debt) 03/2024 ​ 0.00% ​ ​ - ​ ​ 3,078,302 Total ​ ​ ​ ​ ​ 41,862,550 ​ ​ 42,432,806 Less: unamortized issuance costs and discount ​ ​ ​ ​ ​ 1,176,690 ​ ​ 1,937,676 Less: short-term lines of credit ​ ​ ​ ​ ​ 3,384,517 ​ ​ 3,371,676 Less: current portion of long-term debt ​ ​ ​ ​ ​ 10,499,532 ​ ​ 10,808,721 Total long-term debt ​ ​ ​ ​ $ 26,801,811 ​ $ 26,314,733

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of lease of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 228,162 ​ $ 789,877 ​ $ 1,442,082 ​ $ 2,676,894 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ 2,912,084 ​ $ 2,858,223 ​ $ 7,591,105 ​ $ 7,889,533 Interest on lease liabilities ​ ​ 4,516,634 ​ ​ 3,203,802 ​ ​ 12,033,035 ​ ​ 8,718,643 Total finance lease cost ​ $ 7,428,718 ​ $ 6,062,025 ​ $ 19,624,140 ​ $ 16,608,176 ​

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Stock-based Compensation
Schedule of stock-based awards activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ Options ​ Weighted Average ​ Remaining Contractual ​ ​ Outstanding ​ Exercise Price ​ Life (Years) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding at December 31, 2022 ​ ​ 34,318 ​ $ 345.00 ​ ​ 7.60 Options exercised ​ ​ — ​ ​ — ​ ​ ​ Options cancelled ​ ​ — ​ ​ — ​ ​ ​ Options outstanding at September 30, 2023 ​ ​ 34,318 ​ $ 345.00 ​ ​ 6.85 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding at December 31, 2023 ​ ​ 27,590 ​ $ 335.75 ​ ​ 6.94 Options exercised ​ ​ — ​ ​ — ​ ​ ​ Options cancelled ​ ​ (3,334) ​ ​ 367.51 ​ ​ ​ Options outstanding at September 30, 2024 ​ ​ 24,256 ​ $ 335.75 ​ ​ 5.68
Schedule of stock options outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expiration ​ Number ​ Number ​ Exercise Date ​ Outstanding ​ Exercisable ​ Price ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 21, 2025 ​ ​ 686 ​ ​ 686 ​ $ 225.00 January 21, 2025 ​ ​ 300 ​ ​ 300 ​ ​ 241.50 January 21, 2025 ​ ​ 1,214 ​ ​ 1,214 ​ ​ 412.50 January 27, 2027 ​ ​ 300 ​ ​ 300 ​ ​ 225.00 May 11, 2027 ​ ​ 1,401 ​ ​ 1,401 ​ ​ 225.00 June 9, 2027 ​ ​ 167 ​ ​ 167 ​ ​ 376.50 January 28, 2028 ​ ​ 300 ​ ​ 300 ​ ​ 241.50 August 4, 2029 ​ ​ 68 ​ ​ 68 ​ ​ 834.00 January 27, 2030 ​ ​ 1,157 ​ ​ 1,157 ​ ​ 225.00 June 30, 2030 ​ ​ 715 ​ ​ 715 ​ ​ 217.50 January 28, 2031 ​ ​ 6,667 ​ ​ 6,667 ​ ​ 241.50 September 9, 2031 ​ ​ 10,780 ​ ​ 10,780 ​ ​ 412.50 December 17, 2031 ​ ​ 501 ​ ​ 501 ​ ​ 525.00 Total ​ ​ 24,256 ​ ​ 24,256 ​ ​ ​
Schedule of changes in restricted stock units	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares (in thousands) Weighted Average Grant-Date Fair Value Per Share ​ ​ ​ ​ ​ ​ ​ Non-vested awards, December 31, 2022 ​ ​ — ​ ​ — Granted ​ ​ 4 ​ $ 151.50 Vested ​ (1) ​ ​ 151.50 Non-vested awards, September 30, 2023 ​ ​ 3 ​ $ 151.50 ​ ​ ​ ​ ​ ​ ​ Non-vested awards, December 31, 2023 ​ ​ 3 ​ $ 151.50 Granted ​ ​ 118 ​ ​ 5.40 Forfeitures ​ ​ (3) ​ ​ 92.48 Vested ​ ​ (1) ​ ​ 151.50 Non-vested awards, September 30, 2024 ​ ​ 117 ​ $ 37.23

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2024
Equity
Schedule of common stock warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ Warrants ​ Weighted Average ​ Remaining Contractual ​ ​ Outstanding ​ Exercise Price ​ Life (years) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding at December 31, 2022 ​ ​ 73,553 ​ $ 294.16 ​ ​ 3.80 Warrants issued ​ ​ 8,250 ​ ​ 60.00 ​ ​ ​ Warrants exercised ​ ​ (9,710) ​ ​ 232.50 ​ ​ ​ Warrants expired ​ ​ (20) ​ ​ 3,750.00 ​ ​ ​ Warrants outstanding at September 30, 2023 ​ ​ 72,073 ​ $ 274.71 ​ ​ 3.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding at December 31, 2023 ​ ​ 135,537 ​ $ 158.16 ​ ​ 4.42 Warrants issued ​ ​ 444,445 ​ ​ 6.80 ​ ​ ​ Warrants amended ​ ​ 71,801 ​ ​ 30.00 ​ ​ ​ Warrants exercised ​ ​ (150,000) ​ ​ 5.34 ​ ​ ​ Warrants outstanding at September 30, 2024 ​ ​ 501,783 ​ $ 50.15 ​ ​ 4.56
Schedule of outstanding warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expiration ​ Number ​ Number ​ Exercise Date ​ Outstanding ​ Exercisable ​ Price ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2024 ​ ​ 3,701 ​ ​ 3,701 ​ $ 1,000.50 October 31, 2025 ​ ​ 108 ​ ​ 108 ​ ​ 187.50 October 31, 2025 ​ ​ 10,444 ​ ​ 10,444 ​ ​ 232.50 February 26, 2026 ​ ​ 1,922 ​ ​ 1,922 ​ ​ 600.00 July 31, 2026 ​ ​ 16,888 ​ ​ 16,888 ​ ​ 232.50 May 31, 2027 ​ ​ 30,674 ​ ​ 30,674 ​ ​ 262.50 September 30, 2029 ​ ​ 294,445 ​ ​ 294,445 ​ ​ 5.34 October 31, 2029 ​ ​ 16,501 ​ ​ 16,501 ​ ​ 30.00 November 30, 2029 ​ ​ 57,250 ​ ​ 57,250 ​ ​ 30.00 December 31, 2029 ​ ​ 5,167 ​ ​ 5,167 ​ ​ 30.00 January 25, 2029 ​ ​ 64,683 ​ ​ 64,683 ​ ​ 30.00 Total ​ ​ 501,783 ​ ​ 501,783 ​ ​ ​ ​

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings per Share
Scheduled of computation of loss per basic and diluted share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 Amounts attributable to Nutex Health Inc.: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss attributable to common stockholders ​ $ (8,788,313) ​ $ (5,542,391) ​ $ (9,516,436) ​ $ (14,168,717) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares used to compute basic EPS ​ ​ 5,100,030 ​ ​ 4,433,704 ​ ​ 4,973,463 ​ ​ 4,383,935 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ (1.72) ​ $ (1.25) ​ $ (1.91) ​ $ (3.23) Diluted ​ $ (1.72) ​ $ (1.25) ​ $ (1.91) ​ $ (3.23)

Supplemental Cash Flows Infor_2

Supplemental Cash Flows Information (Tables)	9 Months Ended
	Sep. 30, 2024
Supplemental Cash Flows Information
Schedule of supplemental cash flows information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2024 2023 Cash paid for interest ​ $ 2,459,932 ​ $ 858,773 Cash paid for income taxes ​ ​ 1,552,000 ​ ​ 737,000 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ Financed capital expenditures ​ ​ 1,039,126 ​ ​ 5,521,759 Acquisition of finance leases ​ ​ 15,628,963 ​ ​ 18,798,667 Exercise of warrants on cashless basis ​ ​ - ​ ​ 1,268 Issuance of restricted stock units ​ ​ - ​ ​ 298,812 Issuance of common stock to Apollo Medical Holdings, Inc. ​ ​ - ​ ​ 1,900,000 Deconsolidation of Real Estate Entity ​ ​ - ​ ​ 4,258,133 Warrant liability related to common stock issuance ​ ​ 7,661,557 ​ ​ - Reverse stock split adjustment ​ ​ 3 ​ ​ - Common stock issued for Employee Stock Purchase Plan ​ ​ 58,805 ​ ​ - Convertible debt converted to common stock ​ ​ 320,688 ​ ​ 5,151,509 Warrants issued with convertible debt ​ ​ - ​ ​ 175,710 Payment for acquisition in common stock ​ ​ 406,158 ​ ​ 750,000 Common stock received in sale of business ​ ​ 30,250 ​ ​ - ​

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Information
Schedule of assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2024 ​ 2023 Assets: ​ ​ ​ ​ ​ ​ Hospital division ​ $ 387,114,599 ​ $ 278,635,841 Population health management division ​ ​ 31,958,362 ​ ​ 83,647,378 Real estate division ​ ​ 19,415,643 ​ ​ 35,962,278 Total Assets ​ $ 438,488,604 ​ $ 398,245,497
Schedule of segment information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2024 2023 ​ 2024 2023 Revenue from external customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ $ 71,732,529 ​ $ 54,585,263 ​ $ 199,366,776 ​ $ 155,485,230 Population health management division ​ ​ 7,062,340 ​ ​ 8,137,709 ​ ​ 22,964,141 ​ ​ 22,491,613 Total revenue ​ $ 78,794,869 ​ $ 62,722,972 ​ $ 222,330,917 ​ $ 177,976,843 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Segment operating income (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ ​ 21,437,835 ​ ​ 7,238,738 ​ ​ 54,700,084 ​ ​ 21,122,489 Population health management division ​ ​ 478,979 ​ ​ (172,525) ​ ​ (64,861) ​ ​ 438,370 Total segment operating income ​ $ 21,916,814 ​ $ 7,066,213 ​ $ 54,635,223 ​ $ 21,560,859 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ ​ 617,159 ​ ​ 2,875,585 ​ ​ 1,908,651 ​ ​ 10,322,487 Real estate division ​ ​ - ​ ​ - ​ ​ - ​ ​ - Total capital expenditures ​ $ 617,159 ​ $ 2,875,585 ​ $ 1,908,651 ​ $ 10,322,487 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue from inter-segment activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Real estate division ​ $ - ​ $ 13,192,549 ​ $ 603,255 ​ $ 13,708,579 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Hospital division ​ ​ 4,514,723 ​ ​ 4,238,498 ​ ​ 11,949,282 ​ ​ 11,518,388 Population health management division ​ ​ 360,395 ​ ​ 401,566 ​ ​ 1,192,695 ​ ​ 1,201,227 Real estate division ​ ​ 97,360 ​ ​ 105,877 ​ ​ 549,507 ​ ​ 189,233 Total depreciation and amortization ​ $ 4,972,478 ​ $ 4,745,941 ​ $ 13,691,484 ​ $ 12,908,848 ​

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2024
Variable Interest Entities
Schedule of consolidated balance sheets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2024 ​ Real Estate ​ Physician ​ AHISP ​ Entities ​ LLCs ​ IPA ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets $ 37,348 ​ $ 8,274,490 ​ $ 13,446,657 Property and equipment, net ​ - ​ ​ 3,668 ​ ​ 100,868 Long-term assets ​ 33,181,530 ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets $ 33,218,878 ​ $ 8,278,158 ​ $ 13,547,525 ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities ​ - ​ ​ 5,019,463 ​ ​ 13,547,525 Long-term liabilities ​ 12,073,186 ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities ​ 12,073,186 ​ ​ 5,019,463 ​ ​ 13,547,525 ​ ​ ​ ​ ​ ​ ​ ​ ​ Equity ​ 21,145,692 ​ ​ 3,258,695 ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities and equity $ 33,218,878 ​ $ 8,278,158 ​ $ 13,547,525 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ Real Estate ​ Physician ​ AHISP ​ Entities ​ LLCs ​ IPA ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets $ 138,342 ​ $ 8,074,928 ​ $ 8,473,486 Property and equipment, net ​ - ​ ​ 3,668 ​ ​ 65,277 Long-term assets ​ 33,089,636 ​ ​ - ​ ​ 36,452 ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets $ 33,227,978 ​ $ 8,078,596 ​ $ 8,575,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities ​ 38,510 ​ ​ 5,648,516 ​ ​ 8,575,215 Long-term liabilities ​ 12,959,171 ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities ​ 12,997,681 ​ ​ 5,648,516 ​ ​ 8,575,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ Equity ​ 20,230,297 ​ ​ 2,430,080 ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities and equity $ 33,227,978 ​ $ 8,078,596 ​ $ 8,575,215

Organization and Operations (De

Organization and Operations (Details)									3 Months Ended
	Jul. 23, 2024	Jul. 02, 2024	Jun. 17, 2024	Apr. 24, 2024	Apr. 10, 2024	Apr. 09, 2024	Jun. 29, 2023	Apr. 01, 2022 shares	Mar. 31, 2024 shares	Mar. 31, 2023 shares	Sep. 30, 2024 employee individual facility state shares	Jun. 30, 2024 shares	Dec. 31, 2023 shares	Sep. 30, 2023 shares	Dec. 31, 2022 shares
Number of hospital facilities | facility											22
Number of states the company operates within | state											10
Number of full time employees | employee											800
Number of contract doctors | individual											230
Partner with physicians | individual											1,700
Conversion ratio	0.1	0.1	0.1	0.067	0.067	0.067
Common stock outstanding											5,215,709	4,987,268	4,511,199	4,471,411	4,334,826
Common stock authorized											950,000,000		950,000,000
Minimum
Conversion ratio			0.5				0.5
Maximum
Conversion ratio			0.063				0.067
Clinigence Holdings, Inc.
Conversion ratio								3.57143%
Common Stock
Common stock issuance (in shares)									444,444	6,667
Merger Agreement | Common Stock | Clinigence Holdings, Inc.
Common stock issuance (in shares)								592,791,712
Nutex Health Inc | Merger Agreement | Nutex Subsidiaries | Nutex Health Holdco LLC
Ownership percentage								84%

Organization and Operations - R

Organization and Operations - Reverse Stock Splits (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Common Stock - Shares	5,215,709	4,471,411	5,215,709	4,471,411	4,987,268	4,511,199	4,334,826
Common stock	$ 5,216	$ 4,472	$ 5,216	$ 4,472		$ 4,511	$ 4,335
Additional paid-in capital	479,024,452	467,377,960	479,024,452	467,377,960		$ 470,521,218	$ 459,144,291
Net loss attributable to common stockholders	$ (8,788,313)	$ (5,542,391)	$ (9,516,436)	$ (14,168,717)
Weighted average shares used to compute basic EPS	5,100,030	4,433,704	4,973,463	4,383,935
Weighted average shares used to compute diluted EPS		4,433,704		4,383,935
Basic, Loss per common share (in dollar per share)	$ (1.72)	$ (1.25)	$ (1.91)	$ (3.23)
Diluted, Loss per common share (in dollar per share)	$ (1.72)	$ (1.25)	$ (1.91)	$ (3.23)
Options, Outstanding, Beginning Balance			27,590	34,318
Options cancelled			3,334
Options, Outstanding, Ending Balance	24,256	34,318	24,256	34,318
Weighted Average Exercise Price, Beginning Balance			$ 335.75	$ 345
Weighted Average Exercise Price, Options Cancelled			367.51
Weighted Average Exercise Price, Ending Balance	$ 335.75	$ 345	$ 335.75	$ 345
Warrants outstanding, beginning balance				73,553
Warrants issued				8,250
Warrants exercised	(150,000)			(9,710)
Warrants expired				(20)
Warrants outstanding, ending balance	501,783	72,073	501,783	72,073
Warrants outstanding, beginning balance (in dollars per share)				$ 294.16
Warrants issued (in dollars per share)				60
Warrants exercised (in dollars per share)				232.50
Warrants expired (in dollars per share)				3,750
Warrants outstanding, ending balance (in dollars per share)		$ 274.71		$ 274.71
Employee Stock Option
Antidilutive securities excluded from computation of earnings per share amount	24,256		24,256	34,318
Warrant
Antidilutive securities excluded from computation of earnings per share amount	501,783		501,783	72,074
Previously Reported
Common Stock - Shares		670,711,741		670,711,741		676,679,911	650,223,840
Common stock		$ 670,712		$ 670,712		$ 676,680	$ 650,224
Additional paid-in capital		466,711,720		466,711,720		$ 469,849,049	$ 458,498,402
Net loss attributable to common stockholders		$ (5,542,391)		$ (14,168,717)
Weighted average shares used to compute basic EPS		665,055,603		657,590,265
Weighted average shares used to compute diluted EPS		665,055,603		657,590,265
Basic, Loss per common share (in dollar per share)		$ (0.01)		$ (0.01)
Diluted, Loss per common share (in dollar per share)		$ (0.01)		$ (0.01)
Options, Outstanding, Beginning Balance				5,147,770
Options, Outstanding, Ending Balance		5,147,770		5,147,770
Weighted Average Exercise Price, Beginning Balance				$ 2.30
Weighted Average Exercise Price, Ending Balance		$ 2.30		$ 2.30
Warrants outstanding, beginning balance				11,033,015
Warrants issued				1,237,500
Warrants exercised				(1,456,453)
Warrants expired				(3,000)
Warrants outstanding, ending balance		10,811,062		10,811,062
Warrants outstanding, beginning balance (in dollars per share)				$ 1.96
Warrants issued (in dollars per share)				1.55
Warrants exercised (in dollars per share)				1.55
Warrants expired (in dollars per share)				25
Warrants outstanding, ending balance (in dollars per share)		$ 2.02		$ 2.02
Previously Reported | Employee Stock Option
Antidilutive securities excluded from computation of earnings per share amount				5,147,770
Previously Reported | Warrant
Antidilutive securities excluded from computation of earnings per share amount				10,811,062
Revision of Prior Period
Common Stock - Shares		(666,240,330)		(666,240,330)		(672,168,712)	(645,889,014)
Common stock		$ (666,240)		$ (666,240)		$ (672,169)	$ (645,889)
Additional paid-in capital		$ 666,240		$ 666,240		$ 672,169	$ 645,889
Weighted average shares used to compute basic EPS		(660,621,899)		(653,206,330)
Weighted average shares used to compute diluted EPS		(660,621,899)		(653,206,330)
Basic, Loss per common share (in dollar per share)		$ (1.23)		$ (3.22)
Diluted, Loss per common share (in dollar per share)		$ (1.23)		$ (3.22)
Options, Outstanding, Beginning Balance				(5,113,452)
Options, Outstanding, Ending Balance		(5,113,452)		(5,113,452)
Weighted Average Exercise Price, Beginning Balance				$ 342.70
Weighted Average Exercise Price, Ending Balance		$ 342.70		$ 342.70
Warrants outstanding, beginning balance				(10,959,462)
Warrants issued				(1,229,250)
Warrants exercised				1,446,743
Warrants expired				2,980
Warrants outstanding, ending balance		(10,738,989)		(10,738,989)
Warrants outstanding, beginning balance (in dollars per share)				$ 292.20
Warrants issued (in dollars per share)				59.60
Warrants exercised (in dollars per share)				230.95
Warrants expired (in dollars per share)				3,725
Warrants outstanding, ending balance (in dollars per share)		$ 272.88		$ 272.88
Revision of Prior Period | Employee Stock Option
Antidilutive securities excluded from computation of earnings per share amount				(5,113,452)
Revision of Prior Period | Warrant
Antidilutive securities excluded from computation of earnings per share amount				(10,738,988)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	3 Months Ended		9 Months Ended		12 Months Ended	30 Months Ended
	Mar. 31, 2023 entity	Jun. 30, 2022 entity	Sep. 30, 2024 USD ($) entity segment	Dec. 31, 2022 entity	Dec. 31, 2023 entity	Sep. 30, 2024 USD ($) entity
Number of deconsolidated Real Estate Entities | entity	1	17	18	18	18	18
Impairment of goodwill			$ 3,197,391
Number of reportable segments | segment			3
Restricted cash			$ 2,900,000			$ 2,900,000
IPAs
Percentage of control			100%
Physician LLC and Real Estate Entities
Ownership percentage			100%			100%

Divestitures (Details)

Divestitures (Details)				3 Months Ended		9 Months Ended
	Oct. 01, 2024 USD ($)	Aug. 31, 2024 USD ($) payment	May 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Oct. 31, 2024 USD ($)	Jul. 31, 2024 USD ($)
Divestitures
Remitted Company stock					$ (30,250)	$ (30,250)
Intangible impairment				$ 425,221		3,898,856
Goodwill impairment loss						3,197,391
Derecognition of goodwill						453,017
Discontinued operations, disposed of by sale | Procare Health, Inc
Divestitures
Consideration for the transaction		$ 100,000	$ 600,000	100,000	100,000	100,000	$ 100,000	$ 100,000
Liabilities			200,000
Remitted Company stock			100,000
Intangible impairment			2,100,000
Goodwill impairment loss			3,200,000
Derecognition of goodwill			$ 500,000
Proceeds from divestitures						500,000
Total revenue				0		400,000
Net loss (before impairment)				0		600,000
Discontinued operations, disposed of by sale | Procare Health, Inc | Subsequent Event
Divestitures
Proceeds from divestitures	$ 100,000
Discontinued operations, disposed of by sale | Clinigence Health, Inc
Divestitures
Total revenue				200,000		900,000
Net loss (before impairment)				$ 200,000		$ 800,000
Assets held-for-sale					1,400,000
Disposal group not discontinued operations | Clinigence Health, Inc
Divestitures
Consideration for the transaction		1,400,000
Intangible impairment		400,000			$ 1,400,000
Proceeds from divestitures		200,000
Disposal group not discontinued operations | Clinigence Health, Inc | Equity Purchase Agreement
Divestitures
Consideration for the transaction		500,000
Working capital adjustments		300,000
Disposal group not discontinued operations | Clinigence Health, Inc | Equity Purchase Agreement October 31, 2024
Divestitures
Consideration for the transaction		200,000
Disposal group not discontinued operations | Clinigence Health, Inc | To Be Paid on December 31, 2024 [Member]
Divestitures
Consideration for the transaction		200,000
Disposal group not discontinued operations | Clinigence Health, Inc | To Be Paid in 2025 [Member]
Divestitures
Consideration for the transaction		$ 300,000
Number of installments | payment		2
Disposal group not discontinued operations | Clinigence Health, Inc | To Be Paid At The End of First And Second Calendar Quarters [Member]
Divestitures
Consideration for the transaction		$ 125,000
Disposal group not discontinued operations | Clinigence Health, Inc | To Be Paid Within Thirty Days After the End of the Holdback Period [Member]
Divestitures
Consideration for the transaction		$ 200,000

Revenue - Disaggregate revenue

Revenue - Disaggregate revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue
Revenues	$ 78,794,869	$ 62,722,972	$ 222,330,917	$ 177,976,843
Hospital division
Disaggregation of Revenue
Revenues	71,732,529	54,585,263	199,366,776	155,485,230
Population health management division
Disaggregation of Revenue
Revenues	$ 7,062,340	$ 8,137,709	$ 22,964,141	$ 22,491,613

Revenue - Insurance Coverage (D

Revenue - Insurance Coverage (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue
Life insurance assumed ratio	100%	100%	100%	100%
Insurance
Disaggregation of Revenue
Life insurance assumed ratio	95%	92%	93%	93%
Self pay
Disaggregation of Revenue
Life insurance assumed ratio	2%	5%	4%	4%
Workers compensation
Disaggregation of Revenue
Life insurance assumed ratio	2%	2%	2%	2%
Medicare/Medicaid
Disaggregation of Revenue
Life insurance assumed ratio	1%	1%	1%	1%

Revenue (Details)

Revenue (Details)	Sep. 30, 2024
Minimum
Percentage of net patient service revenue	90%

Property and Equipment - Catego

Property and Equipment - Categories (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment
Property and equipment, gross	$ 101,851,407	$ 99,728,712
Less: accumulated depreciation	(23,604,940)	(18,341,063)
Total property and equipment, net	$ 78,246,467	81,387,649
Buildings and improvements
Property, Plant and Equipment
Useful Life (years)	39 years
Property and equipment, gross	$ 19,649,964	18,947,818
Land
Property, Plant and Equipment
Property and equipment, gross	4,410,749	4,401,888
Leasehold improvements
Property, Plant and Equipment
Property and equipment, gross	$ 28,047,662	27,606,383
Leasehold improvements | Minimum
Property, Plant and Equipment
Useful Life (years)	10 years
Leasehold improvements | Maximum
Property, Plant and Equipment
Useful Life (years)	39 years
Construction in progress
Property, Plant and Equipment
Property and equipment, gross	$ 1,777,318	3,776,138
Medical equipment
Property, Plant and Equipment
Useful Life (years)	10 years
Property and equipment, gross	$ 34,824,092	33,519,026
Office furniture and equipment
Property, Plant and Equipment
Useful Life (years)	7 years
Property and equipment, gross	$ 3,973,548	3,698,874
Computer hardware and software
Property, Plant and Equipment
Useful Life (years)	5 years
Property and equipment, gross	$ 7,013,106	6,066,520
Vehicles
Property, Plant and Equipment
Useful Life (years)	5 years
Property and equipment, gross	$ 94,433	135,590
Signage
Property, Plant and Equipment
Useful Life (years)	10 years
Property and equipment, gross	$ 2,060,535	$ 1,576,475

Property and Equipment (Details

Property and Equipment (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 item	Sep. 30, 2024 entity	Sep. 30, 2023 USD ($)
Property, Plant and Equipment
Number of real estate entities consolidated				2	2
Depreciation and amortization	$ 4,972,478	$ 4,745,941	$ 13,691,484			$ 12,908,848
Property, plant and equipment
Property, Plant and Equipment
Depreciation and amortization	$ 1,800,000	$ 1,600,000	$ 5,000,000			$ 4,000,000

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Components (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 18,965,000		$ 18,965,000		$ 23,261,795
Accumulated Amortization	3,109,608		3,109,608		2,749,159
Net Carrying Amount	15,855,392		15,855,392		20,512,636
Amortization of intangible assets	300,000	$ 400,000	1,100,000	$ 1,200,000
Impairment loss	400,000		3,900,000
Member relationships
Finite-Lived Intangible Assets
Gross Carrying Amount	18,491,000		18,491,000		18,491,000
Accumulated Amortization	2,940,318		2,940,318		2,015,772
Net Carrying Amount	$ 15,550,682		$ 15,550,682		$ 16,475,228
Weighted Average Useful Life (in years)	15 years		15 years		15 years
Management contracts
Finite-Lived Intangible Assets
Gross Carrying Amount					$ 2,021,000
Accumulated Amortization					221,047
Net Carrying Amount					$ 1,799,953
Weighted Average Useful Life (in years)					16 years
Customer contracts
Finite-Lived Intangible Assets
Gross Carrying Amount					$ 914,000
Accumulated Amortization					106,633
Net Carrying Amount					$ 807,367
Weighted Average Useful Life (in years)					15 years
Trademarks
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 474,000		$ 474,000		$ 1,426,795
Accumulated Amortization	169,290		169,290		262,557
Net Carrying Amount	$ 304,710		$ 304,710		$ 1,164,238
Weighted Average Useful Life (in years)	7 years		7 years
Trademarks | Minimum
Finite-Lived Intangible Assets
Weighted Average Useful Life (in years)	7 years		7 years		7 years
Trademarks | Maximum
Finite-Lived Intangible Assets
Weighted Average Useful Life (in years)					12 years
PHP technology
Finite-Lived Intangible Assets
Gross Carrying Amount					$ 409,000
Accumulated Amortization					143,150
Net Carrying Amount					$ 265,850
Weighted Average Useful Life (in years)					5 years

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Operating Segment (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets and Goodwill
Goodwill		$ 416,390,445	$ 416,340,598
Accumulated impairment losses		(402,471,726)	(399,274,335)
Goodwill, Total		13,918,719	17,066,263
Purchase accounting adjustments		502,864
Impairment of goodwill		(3,197,391)
Derecognition of goodwill		(453,017)
Hospital Division
Intangible Assets and Goodwill
Goodwill		1,139,297	1,139,297
Accumulated impairment losses		(1,139,297)	(1,139,297)
Population Health Management Division
Intangible Assets and Goodwill
Goodwill		415,251,148	415,201,301
Accumulated impairment losses		(401,332,429)	(398,135,038)
Goodwill, Total		13,918,719	$ 17,066,263
Purchase accounting adjustments	$ 500,000	502,864
Impairment of goodwill		(3,197,391)
Derecognition of goodwill		$ (453,017)

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Details)	3 Months Ended			9 Months Ended
	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2023 USD ($) item	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Intangible Assets and Goodwill
Purchase accounting adjustments				$ 502,864
Loss on sale of business				3,197,391
Goodwill	$ 13,918,719			13,918,719	$ 17,066,263
Population Health Management Division
Intangible Assets and Goodwill
Purchase accounting adjustments			$ 500,000	502,864
Florida based IPAs | item			2
Loss on sale of business				3,197,391
Goodwill	13,918,719			13,918,719	$ 17,066,263
Goodwill impairment	$ 0	$ 0		$ 0

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities
Accrued wages and benefits	$ 12,279,378	$ 6,590,710
Accrued supplier expenses	1,528,692
Accrued medical insurance claims	4,023,293	1,865,280
Accrued taxes	7,580,859	405,352
Accrued other	4,276,443	4,093,954
Total accrued expenses and other current liabilities	$ 29,688,665	$ 12,955,296

Debt - Outstanding Debt (Detail

Debt - Outstanding Debt (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument
Total	$ 41,862,550	$ 42,432,806
Less: unamortized issuance costs and discount	1,176,690	1,937,676
Less: short-term lines of credit	3,384,517	3,371,676
Less: current portion of long-term debt	10,499,532	10,808,721
Long-term debt, net	26,801,811	26,314,733
Term loans secured by all assets
Debt Instrument
Total	$ 9,450,020	$ 7,030,613
Term loans secured by all assets | Minimum
Debt Instrument
Interest Rates (as percentage)	4%	4%
Term loans secured by all assets | Maximum
Debt Instrument
Interest Rates (as percentage)	12%	12%
Term loans secured by property and equipment
Debt Instrument
Total	$ 9,184,930	$ 10,562,207
Term loans secured by property and equipment | Minimum
Debt Instrument
Interest Rates (as percentage)	3.41%	3.41%
Term loans secured by property and equipment | Maximum
Debt Instrument
Interest Rates (as percentage)	7.82%	7.82%
Line of credit secured by all assets
Debt Instrument
Total	$ 3,384,517	$ 3,371,675
Line of credit secured by all assets | Minimum
Debt Instrument
Interest Rates (as percentage)	7.75%	7.75%
Line of credit secured by all assets | Maximum
Debt Instrument
Interest Rates (as percentage)	9.50%	9.50%
Term loans of consolidated Real Estate Entities
Debt Instrument
Total	$ 12,116,455	$ 13,005,019
Term loans of consolidated Real Estate Entities | Minimum
Debt Instrument
Interest Rates (as percentage)	3.50%	3.50%
Term loans of consolidated Real Estate Entities | Maximum
Debt Instrument
Interest Rates (as percentage)	3.59%	3.59%
Term loan secured by deposits
Debt Instrument
Interest Rates (as percentage)	7.36%	7.36%
Total	$ 2,341,638
Unsecured convertible term notes
Debt Instrument
Total	$ 5,384,990	$ 5,384,990
Unsecured convertible term notes | Minimum
Debt Instrument
Interest Rates (as percentage)	8%	8%
Unsecured convertible term notes | Maximum
Debt Instrument
Interest Rates (as percentage)	10%	10%
Prepaid Advance
Debt Instrument
Interest Rates (as percentage)	0%	0%
Total		$ 3,078,302

Debt - Term Loans and Lines of

Debt - Term Loans and Lines of Credit (Details) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended	30 Months Ended
	Mar. 31, 2023 entity	Jun. 30, 2022 entity	Sep. 30, 2024 USD ($) entity	Dec. 31, 2022 entity	Dec. 31, 2023 USD ($) loan entity	Sep. 30, 2024 USD ($) entity
Debt
Number of deconsolidated Real Estate Entities | entity	1	17	18	18	18	18
Number of loans | loan					1
Debt instrument not in compliance with debt service coverage ratio					$ 0.3
Outstanding balance			$ 0			$ 0
Remaining borrowing capacity			$ 4.1			$ 4.1

Debt - Pre-Paid Advance Agreeme

Debt - Pre-Paid Advance Agreement (Details)				3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 26, 2024 $ / shares shares	Jan. 22, 2024 USD ($)	Apr. 11, 2023 USD ($) D shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($)	Jul. 23, 2024 $ / shares	Jul. 22, 2024 $ / shares	Apr. 26, 2024 $ / shares	Apr. 25, 2024 $ / shares	Dec. 31, 2022
Debt Instrument
Warrant duration				5 years	5 years
Strike price | $ / shares								$ 5.34	$ 6.80	$ 0.68	$ 2.25
Net Proceeds						$ 891,000
Debt Issuance Costs				$ 1,176,690	$ 1,176,690		$ 1,937,676
Debt, Converted Instrument, Amount					320,688	$ 5,151,509
Net cash proceeds, received		$ 9,200,000
Gross proceeds					$ 9,202,500
Debt issuance costs		$ 800,000
Prior to Reverse Stock Split
Debt Instrument
Warrants issued to purchase of common stock | shares				4,038,750	4,038,750
Accredited Investors Warrants
Debt Instrument
Warrants issued to purchase of common stock | shares				44,875	44,875
Strike price | $ / shares				$ 60	$ 60
Accredited Investors Warrants | Prior to Reverse Stock Split
Debt Instrument
Warrants issued to purchase of common stock | shares				6,731,250	6,731,250
Strike price | $ / shares				$ 0.40	$ 0.40
Common Stock Warrants
Debt Instrument
Warrant duration				4 years 6 months 21 days	4 years 6 months 21 days	3 years 4 months 6 days	4 years 5 months 1 day					3 years 9 months 18 days
Warrants issued to purchase of common stock | shares	89,750			444,445	444,445	8,250
Strike price | $ / shares	$ 30
Common Stock Warrants | Prior to Reverse Stock Split
Debt Instrument
Warrants issued to purchase of common stock | shares	13,462,500
Placement Agent Warrants
Debt Instrument
Warrants issued to purchase of common stock | shares	53,850
Placement Agent Warrants | Prior to Reverse Stock Split
Debt Instrument
Warrants issued to purchase of common stock | shares	8,077,500			26,925	26,925
September 2023 Private Offering
Debt Instrument
Warrant duration				6 years	6 years
Conversion price per share | $ / shares				$ 30	$ 30
Interest rate paid in cash (as a percent)					8%
Interest rate paid in kind (as a percent)					10%
Grace days for payment of outstanding principal amount and accrued interests					30 days
Adjusted interest rate payable					12%
Interest Rate, Effective Percentage				21.50%	21.50%
Emerson Equity LLC ("Emerson") | September 2023 Private Offering
Debt Instrument
Cash commission payable (as a percent)				10%	10%
Percentage of warrants to purchase common stock on total units				20%	20%
Prepaid Advance
Debt Instrument
Interest Rates (as percentage)					0%		0%
Prepaid Advance | Yorkville | Pre-Paid Advance Agreement with Yorkville
Debt Instrument
Percentage of the face amount for issue			90%
Initial pre-paid advance amount with expenses			$ 15,000,000
Interest Rates (as percentage)			0%
Interest Rate Upon Events of Default			15%
Maturity date			12 months
Prepayment, Threshold Consecutive Trading Days | D			10
Prepayment, Notice Period			10 days
Prepayment Premium			6%
Net Proceeds			$ 13,500,000
Percentage of debt discount			10%
Debt discount			$ 1,500,000
Debt Issuance Costs			$ 900,000
Convertible notes, converted to shares | shares			200,000
Debt, Converted Instrument, Amount			$ 7,300,000
Optional prepayment			8,200,000
Convertible Debt, Principal			7,700,000
Prepayment Premium			$ 1,000,000
Prepaid Advance | Yorkville | Pre-Paid Advance Agreement with Yorkville | Prior to Reverse Stock Split
Debt Instrument
Convertible notes, converted to shares | shares			23,100,000
Convertible debt
Debt Instrument
Conversion price per share | $ / shares	$ 30			$ 60	$ 60
Additional number of common shares issuable | shares	179,500				89,751
Convertible debt | Prior to Reverse Stock Split
Debt Instrument
Conversion price per share | $ / shares	$ 0.20			$ 0.40	$ 0.40
Additional number of common shares issuable | shares	26,925,000				13,462,500
Convertible debt | September 2023 Private Offering
Debt Instrument
Net carrying amount				$ 4,300,000	$ 4,300,000
Interest Expense				300,000
Amortization expense				200,000
Accrued interest expense				100,000	100,000
Convertible debt | September 2023 Private Offering As Amended
Debt Instrument
Interest Expense					1,000,000
Amortization expense					700,000
Accrued interest expense				$ 300,000	$ 300,000
Convertible debt | Maximum
Debt Instrument
Interest Rates (as percentage)					10%		10%
Convertible debt | Minimum
Debt Instrument
Interest Rates (as percentage)					8%		8%

Leases - Leases of property and

Leases - Leases of property and equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating lease cost	$ 228,162	$ 789,877	$ 1,442,082	$ 2,676,894
Finance lease cost:
Amortization of right-of-use assets	2,912,084	2,858,223	7,591,105	7,889,533
Interest on lease liabilities	4,516,634	3,203,802	12,033,035	8,718,643
Total finance lease cost	$ 7,428,718	$ 6,062,025	$ 19,624,140	$ 16,608,176

Stock-based Compensation (Detai

Stock-based Compensation (Details) $ / shares in Units, $ in Millions										3 Months Ended	9 Months Ended
	Jul. 23, 2024	Jul. 02, 2024	Jun. 17, 2024	Jun. 16, 2024 USD ($) shares	Apr. 24, 2024	Apr. 10, 2024	Apr. 09, 2024	Jun. 29, 2023	Apr. 01, 2023 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares
Share-Based Payment Arrangement
Shares issued and outstanding								1%
Conversion ratio	0.1	0.1	0.1		0.067	0.067	0.067
Accrued stock based compensation | $										$ 1.9	$ 1.7
Restricted Stock
Share-Based Payment Arrangement
Restricted common stock awards issued (in shares) | shares				118,538					4,035
Restricted common stock awards issued | $				$ 0.6					$ 0.6
Prior to Reverse Stock Split | Restricted Stock
Share-Based Payment Arrangement
Restricted common stock awards issued (in shares) | shares									604,158
Equity Incentive 2022 Plan
Share-Based Payment Arrangement
Multiplying factor											10
Share price										$ 2.80	$ 2.80
Equity Incentive 2022 Plan | Prior to Reverse Stock Split
Share-Based Payment Arrangement
Share price										2.80	2.80
Equity Incentive 2022 Plan | After the reverse stock split
Share-Based Payment Arrangement
Share price										$ 420	$ 420

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-Based Awards Activity (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement Roll-Forward
Options, Outstanding, Beginning Balance	27,590	34,318	34,318
Options cancelled	(3,334)
Options, Outstanding, Ending Balance	24,256	34,318	27,590	34,318
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 335.75	$ 345	$ 345
Weighted Average Exercise Price, Options Cancelled	367.51
Weighted Average Exercise Price, Ending Balance	$ 335.75	$ 345	$ 335.75	$ 345
Weighted Average Remaining Contractual Life (Years)	5 years 8 months 4 days	6 years 10 months 6 days	6 years 11 months 8 days	7 years 7 months 6 days

Stock-based Compensation - Opti

Stock-based Compensation - Options Outstanding (Details) - $ / shares	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement
Number Outstanding	24,256	27,590	34,318	34,318
Number Exercisable	24,256
Exercise Price	$ 335.75	$ 335.75	$ 345	$ 345
January 21, 2025
Share-Based Payment Arrangement
Number Outstanding	686
Number Exercisable	686
Exercise Price	$ 225
January 21, 2025
Share-Based Payment Arrangement
Number Outstanding	300
Number Exercisable	300
Exercise Price	$ 241.50
January 21, 2025
Share-Based Payment Arrangement
Number Outstanding	1,214
Number Exercisable	1,214
Exercise Price	$ 412.50
January 27, 2027
Share-Based Payment Arrangement
Number Outstanding	300
Number Exercisable	300
Exercise Price	$ 225
May 11, 2027
Share-Based Payment Arrangement
Number Outstanding	1,401
Number Exercisable	1,401
Exercise Price	$ 225
June 9, 2027
Share-Based Payment Arrangement
Number Outstanding	167
Number Exercisable	167
Exercise Price	$ 376.50
January 28, 2028
Share-Based Payment Arrangement
Number Outstanding	300
Number Exercisable	300
Exercise Price	$ 241.50
August 4, 2029
Share-Based Payment Arrangement
Number Outstanding	68
Number Exercisable	68
Exercise Price	$ 834
January 27, 2030
Share-Based Payment Arrangement
Number Outstanding	1,157
Number Exercisable	1,157
Exercise Price	$ 225
June 30, 2030
Share-Based Payment Arrangement
Number Outstanding	715
Number Exercisable	715
Exercise Price	$ 217.50
January 28, 2031
Share-Based Payment Arrangement
Number Outstanding	6,667
Number Exercisable	6,667
Exercise Price	$ 241.50
September 9, 2031
Share-Based Payment Arrangement
Number Outstanding	10,780
Number Exercisable	10,780
Exercise Price	$ 412.50
December 17, 2031
Share-Based Payment Arrangement
Number Outstanding	501
Number Exercisable	501
Exercise Price	$ 525

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units Issued and Vested (Details) - RSUs - shares			9 Months Ended
	Jun. 16, 2024	Apr. 01, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement
Vested			1,000	1,000
Vested on April 1, 2023
Share-Based Payment Arrangement
Vested		1,431
Vested on March 1, 2024
Share-Based Payment Arrangement
Vested		1,298
Vest on March 1, 2025
Share-Based Payment Arrangement
Vested	39,514	1,306
Vest on March 1 2026
Share-Based Payment Arrangement
Vested	39,514
Vest on March 1 2027
Share-Based Payment Arrangement
Vested	39,510
Prior to Reverse Stock Split | Vested on April 1, 2023
Share-Based Payment Arrangement
Vested		214,720
Prior to Reverse Stock Split | Vested on March 1, 2024
Share-Based Payment Arrangement
Vested		194,720
Prior to Reverse Stock Split | Vest on March 1, 2025
Share-Based Payment Arrangement
Vested	1,184,946	194,720

Stock-based Compensation - Re_2

Stock-based Compensation - Restricted Stock Units (Details) - RSUs $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($) item $ / shares shares	Sep. 30, 2023 $ / shares shares
Share-Based Payment Arrangement Rollforward
Beginning balance | shares	3
Granted | shares	118	4
Forfeitures | shares	(3)
Vested | shares	(1)	(1)
Ending balance | shares	117	3
Weighted Average Grant-Date Fair Value Per Share
Beginning balance | $ / shares	$ 151.50
Granted | $ / shares	5.40	$ 151.50
Forfeitures | $ / shares	92.48
Vested | $ / shares	151.50	151.50
Ending balance | $ / shares	$ 37.23	$ 151.50
Unrecognized compensation cost | $	$ 0.7
Share-based award vesting period	1 year 8 months 12 days
Vesting Rights, Percentage	33.33%
Award Vesting, Number of Anniversaries | item	3

Stock-based Compensation - Empl

Stock-based Compensation - Employee Stock Purchase Plan (Details) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	May 31, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement
Common stock issued for Employee Stock Purchase Plan		$ 25,370	$ 14,409	$ 19,026
2023 Employee Stock Purchase Plan
Share-Based Payment Arrangement
Shares authorized	33,333		118,563			73,426
Percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan	85%
Common stock issued for Employee Stock Purchase Plan (in shares)		4,300			7,107
Common stock issued for Employee Stock Purchase Plan		$ 100,000			$ 100,000
2023 Employee Stock Purchase Plan | Prior to Reverse Stock Split
Share-Based Payment Arrangement
Shares authorized	5,000,000					11,013,943

Equity (Details)

Equity (Details)									3 Months Ended					9 Months Ended
	Jul. 23, 2024 $ / shares	Jul. 02, 2024	Jun. 17, 2024	Apr. 24, 2024	Apr. 10, 2024	Apr. 09, 2024	Mar. 26, 2024 $ / shares shares	Jan. 22, 2024 USD ($) D $ / shares shares	Sep. 30, 2024 USD ($) Vote $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Sep. 30, 2024 USD ($) Vote $ / shares shares	Sep. 30, 2023 USD ($) shares	Jul. 22, 2024 $ / shares	Apr. 26, 2024 $ / shares	Apr. 25, 2024 $ / shares	Jan. 25, 2024 USD ($)	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 shares
Accumulated Other Comprehensive Income (Loss)
Common stock authorized									950,000,000					950,000,000						950,000,000
Common stock, par value | $ / shares									$ 0.001					$ 0.001						$ 0.001
Number of votes entitled to each common stock holders | Vote									1					1
Stock-based compensation | $									$ 1,963,518			$ 49,167		$ 1,951,444	$ 2,198,812
Warrants outstanding									501,783			72,073		501,783	72,073						73,553
Warrant duration									5 years					5 years
Gross proceeds | $								$ 9,200,000
Warrant liability related to common stock issuance | $								7,700,000						$ 7,661,557
Allocation of proceeds related to common stock issuance | $								1,500,000			$ 1,540,943		$ 1,900,000		$ 1,900,000
Offering expenses | $								$ 800,000
Warrant liability | $									$ 5,715,143					5,715,143					$ 7,700,000
Warrants exercised									150,000						9,710
Proceeds for exercised warrants | $									$ 800,000
Adjustment of Warrants | $									$ (6,700,000)					$ (1,100,000)
Weighted average prices								100%
Trading days | D								10
Conversion ratio	0.1	0.1	0.1	0.067	0.067	0.067
Strike price | $ / shares	$ 5.34															$ 6.80	$ 0.68	$ 2.25
Common Stock
Accumulated Other Comprehensive Income (Loss)
Common stock issued for acquisition (in shares)									47,106	17,640		16,943
Common stock issuance (in shares)											444,444		6,667
Allocation of proceeds related to common stock issuance | $											$ 444		$ 7
Prior to Reverse Stock Split
Accumulated Other Comprehensive Income (Loss)
Warrants issued to purchase of common stock									4,038,750					4,038,750
Volatility | Level 3
Accumulated Other Comprehensive Income (Loss)
Fair value of the warrant								120
Common Stock Warrants
Accumulated Other Comprehensive Income (Loss)
Warrants outstanding									501,783			72,073		501,783	72,073					135,537	73,553
Warrants issued to purchase of common stock							89,750		444,445			8,250		444,445	8,250
Warrant duration									4 years 6 months 21 days			3 years 4 months 6 days		4 years 6 months 21 days	3 years 4 months 6 days					4 years 5 months 1 day	3 years 9 months 18 days
Warrants exercised														150,000	9,710
Strike price | $ / shares							$ 30
Warrants amended							71,801							71,801
Common Stock Warrants | Prior to Reverse Stock Split
Accumulated Other Comprehensive Income (Loss)
Warrants issued to purchase of common stock							13,462,500
Warrants amended							10,770,000
Securities purchase agreement
Accumulated Other Comprehensive Income (Loss)
Common stock, par value | $ / shares								$ 0.001
Common stock issuance (in shares)								444,445
Warrants issued to purchase of common stock								444,445
Warrants issued ratio								1
Offering price | $ / shares								$ 22.50
Warrant duration								5 years
Percentage of beneficially owned by such holder								4.99%
Percentage of beneficially owned by the issuance of any warrants								9.99%
Strike price | $ / shares								$ 22.50
Securities purchase agreement | Prior to Reverse Stock Split
Accumulated Other Comprehensive Income (Loss)
Common stock issuance (in shares)								66,666,666
Warrants issued to purchase of common stock								66,666,666
Offering price | $ / shares								$ 0.15
Strike price | $ / shares								$ 0.15
Securities purchase agreement | Common Stock Warrants
Accumulated Other Comprehensive Income (Loss)
Common stock issuance (in shares)														444,445
Offering price | $ / shares									$ 22.50					$ 22.50
Securities purchase agreement | Common Stock Warrants | Prior to Reverse Stock Split
Accumulated Other Comprehensive Income (Loss)
Common stock issuance (in shares)														66,666,666
Offering price | $ / shares									$ 0.15					$ 0.15

Equity - Common Stock Warrants

Equity - Common Stock Warrants (Details) - $ / shares		3 Months Ended	9 Months Ended
	Mar. 26, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Warrants Outstanding
Warrants outstanding, beginning balance				73,553
Warrants exercised		(150,000)		(9,710)
Warrants expired				(20)
Warrants outstanding, ending balance		501,783	501,783	72,073
Warrants Weighted Average Exercise Price
Warrants outstanding, beginning balance (in dollars per share)				$ 294.16
Warrant issued (in dollar per share)				60
Warrants exercised (in dollars per share)				232.50
Warrants expired (in dollars per share)				3,750
Warrants outstanding, ending balance (in dollars per share)				$ 274.71
Warrants Weighted Average Remaining Contractual Life (years)		5 years	5 years
Common Stock Warrants
Warrants Outstanding
Warrants outstanding, beginning balance			135,537	73,553
Warrants issued	89,750	444,445	444,445	8,250
Warrants amended	71,801		71,801
Warrants exercised			(150,000)	(9,710)
Warrants expired				(20)
Warrants outstanding, ending balance		501,783	501,783	72,073
Warrants Weighted Average Exercise Price
Warrants outstanding, beginning balance (in dollars per share)			$ 158.16	$ 294.16
Warrant issued (in dollar per share)			6.80	60
Warrants amended (in dollars per share)			30
Warrants exercised (in dollars per share)			5.34	232.50
Warrants expired (in dollars per share)				3,750
Warrants outstanding, ending balance (in dollars per share)		$ 50.15	$ 50.15	$ 274.71
Warrants Weighted Average Remaining Contractual Life (years)		4 years 6 months 21 days	4 years 6 months 21 days	3 years 4 months 6 days	4 years 5 months 1 day	3 years 9 months 18 days

Equity - Schedule of Outstandin

Equity - Schedule of Outstanding Warrants (Details) - $ / shares	Sep. 30, 2024	Jul. 23, 2024	Jul. 22, 2024	Apr. 26, 2024	Apr. 25, 2024	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement
Number Outstanding	501,783					72,073	73,553
Number Exercisable	501,783
Exercise Price		$ 5.34	$ 6.80	$ 0.68	$ 2.25
December 31, 2024
Share-Based Payment Arrangement
Number Outstanding	3,701
Number Exercisable	3,701
Exercise Price	$ 1,000.50
October 31, 2025
Share-Based Payment Arrangement
Number Outstanding	108
Number Exercisable	108
Exercise Price	$ 187.50
October 31, 2025
Share-Based Payment Arrangement
Number Outstanding	10,444
Number Exercisable	10,444
Exercise Price	$ 232.50
February 26, 2026
Share-Based Payment Arrangement
Number Outstanding	1,922
Number Exercisable	1,922
Exercise Price	$ 600
July 31, 2026
Share-Based Payment Arrangement
Number Outstanding	16,888
Number Exercisable	16,888
Exercise Price	$ 232.50
May 31, 2027
Share-Based Payment Arrangement
Number Outstanding	30,674
Number Exercisable	30,674
Exercise Price	$ 262.50
September 30, 2029
Share-Based Payment Arrangement
Number Outstanding	294,445
Number Exercisable	294,445
Exercise Price	$ 5.34
October 31, 2029
Share-Based Payment Arrangement
Number Outstanding	16,501
Number Exercisable	16,501
Exercise Price	$ 30
November 30, 2029
Share-Based Payment Arrangement
Number Outstanding	57,250
Number Exercisable	57,250
Exercise Price	$ 30
December 31, 2029
Share-Based Payment Arrangement
Number Outstanding	5,167
Number Exercisable	5,167
Exercise Price	$ 30
January 25, 2029
Share-Based Payment Arrangement
Number Outstanding	64,683
Number Exercisable	64,683
Exercise Price	$ 30

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Income Taxes
Effective tax rate	177.70%	501.20%
Federal statutory rate		21%

Earnings per Share - Computatio

Earnings per Share - Computation of EPS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net loss attributable to common stockholders	$ (8,788,313)	$ (5,542,391)	$ (9,516,436)	$ (14,168,717)
Denominator:
Weighted average shares used to compute basic EPS	5,100,030	4,433,704	4,973,463	4,383,935
Weighted average shares used to compute diluted EPS		4,433,704		4,383,935
Earnings per share, pro forma
Basic	$ (1.72)	$ (1.25)	$ (1.91)	$ (3.23)
Diluted	$ (1.72)	$ (1.25)	$ (1.91)	$ (3.23)

Earnings per Share (Details)

Earnings per Share (Details) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Employee Stock Option
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	24,256	24,256	34,318
Employee Stock Option | Prior to Reverse Stock Split
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	3,638,355	3,638,355	5,147,770
Warrant
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	501,783	501,783	72,074
Warrant | Prior to Reverse Stock Split
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	75,267,450	75,267,450	10,811,062
RSUs
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	1,298	1,298
RSUs | Prior to Reverse Stock Split
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	194,720	194,720
Convertible debt securities
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	179,500	179,500
Convertible debt securities | Prior to Reverse Stock Split
Earnings per Share
Antidilutive securities excluded from computation of earnings per share amount	26,925,000	26,925,000

Supplemental Cash Flows Infor_3

Supplemental Cash Flows Information (Details) - USD ($)		3 Months Ended					9 Months Ended
	Jan. 22, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Supplemental Cash Flows Information
Cash paid for interest							$ 2,459,932	$ 858,773
Cash paid for income taxes							1,552,000	737,000
Cash Flow, Noncash Investing and Financing Activities Disclosure
Financed capital expenditures							1,039,126	5,521,759
Acquisition of finance leases							15,628,963	18,798,667
Exercise of warrants on cashless basis								1,268
Issuance of restricted stock units								298,812
Issuance of common stock to Apollo Medical Holdings, Inc.	$ 1,500,000			$ 1,540,943		$ 1,900,000		1,900,000
Deconsolidation of Real Estate Entity								4,258,133
Warrant liability related to common stock issuance	$ 7,700,000						7,661,557
Reverse stock split adjustment							3
Common stock issued for Employee Stock Purchase Plan							58,805
Convertible debt converted to common stock							320,688	5,151,509
Warrants issued with convertible debt								175,710
Payment for acquisition in common stock		$ 250,000	$ 156,158		$ 750,000		406,158	$ 750,000
Common stock received in sale of business			$ 30,250				$ 30,250

Segment Information - Assets (D

Segment Information - Assets (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) segment	Dec. 31, 2023 USD ($)
Segment Information
Number of reportable segments | segment	3
Total Assets	$ 438,488,604	$ 398,245,497
Hospital division
Segment Information
Total Assets	387,114,599	278,635,841
Population health management division
Segment Information
Total Assets	31,958,362	83,647,378
Real estate division
Segment Information
Total Assets	$ 19,415,643	$ 35,962,278

Segment Information - Operation

Segment Information - Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Information
Total revenue	$ 78,794,869	$ 62,722,972	$ 222,330,917	$ 177,976,843
Total segment operating income	21,916,814	7,066,213	54,635,223	21,560,859
Total capital expenditures	617,159	2,875,585	1,908,651	10,322,487
Total depreciation and amortization	4,972,478	4,745,941	13,691,484	12,908,848
Hospital division | Operating Segment
Segment Information
Total revenue	71,732,529	54,585,263	199,366,776	155,485,230
Total segment operating income	21,437,835	7,238,738	54,700,084	21,122,489
Total capital expenditures	617,159	2,875,585	1,908,651	10,322,487
Total depreciation and amortization	4,514,723	4,238,498	11,949,282	11,518,388
Population health management division | Operating Segment
Segment Information
Total revenue	7,062,340	8,137,709	22,964,141	22,491,613
Total segment operating income	478,979	(172,525)	(64,861)	438,370
Total depreciation and amortization	360,395	401,566	1,192,695	1,201,227
Real estate division | Operating Segment
Segment Information
Total depreciation and amortization	$ 97,360	105,877	549,507	189,233
Real estate division | Intersegment Eliminations
Segment Information
Total revenue		$ 13,192,549	$ 603,255	$ 13,708,579

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended				9 Months Ended			12 Months Ended	30 Months Ended
	Sep. 30, 2024 USD ($) entity	Sep. 30, 2023 USD ($) entity	Mar. 31, 2023 entity	Jun. 30, 2022 entity	Sep. 30, 2024 USD ($) entity	Sep. 30, 2023 USD ($) entity	Dec. 31, 2022 entity	Dec. 31, 2023 USD ($) entity	Sep. 30, 2024 USD ($) entity
Related Party Transactions
Net expense	$ 6,417,886	$ 9,541,894			$ 23,380,318	$ 25,215,549
Accounts Payable, Related Parties	$ 200,000				$ 200,000			$ 900,000	$ 200,000
Number of deconsolidated Real Estate Entities | entity			1	17	18		18	18	18
Number of consolidated real estate entity | entity	2				2				2
Accounts payable	$ 10,320,933				$ 10,320,933			$ 18,899,196	$ 10,320,933
Revenues	78,794,869	62,722,972			222,330,917	177,976,843
Hospital division
Related Party Transactions
Lease obligation payments	5,100,000	$ 3,900,000			14,700,000	$ 11,100,000
Managerial Services Agreements
Related Party Transactions
Number of ER Entities operated | entity		2				2
Managerial Services Agreements | Hospital division
Related Party Transactions
Revenues		$ 100,000				$ 500,000
Physician LLCs
Related Party Transactions
Accounts Payable, Related Parties	3,500,000				3,500,000			2,900,000	3,500,000
ER Entities
Related Party Transactions
Accounts Receivable, Related Parties	3,600,000				3,600,000			4,100,000	3,600,000
ER Entities | Managerial Services Agreements
Related Party Transactions
Repayments of related party debt		$ 100,000				$ 500,000
Micro Hospital Holding LLC
Related Party Transactions
Accounts payable	$ 1,400,000				$ 1,400,000			$ 1,200,000	$ 1,400,000

Variable Interest Entities - Ba

Variable Interest Entities - Balance sheet amounts (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Mar. 31, 2023
Variable Interest Entities
Current assets	$ 119,795,334	$ 90,848,403
Property and equipment, net	78,246,467	81,387,649
Total assets	438,488,604	398,245,497
Current liabilities	67,558,746	58,313,052
Total liabilities	358,710,179	319,139,391
Equity	60,440,693	61,453,190
Total liabilities and equity	438,488,604	398,245,497
Real Estate Entities
Variable Interest Entities
Property and equipment, net			$ 8,400,000
Total liabilities			$ 5,400,000
Primary Beneficiary | Real Estate Entities
Variable Interest Entities
Current assets	37,348	138,342
Long-term assets	33,181,530	33,089,636
Total assets	33,218,878	33,227,978
Current liabilities		38,510
Long-term liabilities	12,073,186	12,959,171
Total liabilities	12,073,186	12,997,681
Equity	21,145,692	20,230,297
Total liabilities and equity	33,218,878	33,227,978
Primary Beneficiary | Physician LLCs
Variable Interest Entities
Current assets	8,274,490	8,074,928
Property and equipment, net	3,668	3,668
Total assets	8,278,158	8,078,596
Current liabilities	5,019,463	5,648,516
Total liabilities	5,019,463	5,648,516
Equity	3,258,695	2,430,080
Total liabilities and equity	8,278,158	8,078,596
Primary Beneficiary | AHISP IPA
Variable Interest Entities
Current assets	13,446,657	8,473,486
Property and equipment, net	100,868	65,277
Long-term assets		36,452
Total assets	13,547,525	8,575,215
Current liabilities	13,547,525	8,575,215
Total liabilities	13,547,525	8,575,215
Total liabilities and equity	$ 13,547,525	$ 8,575,215

Variable Interest Entities (Det

Variable Interest Entities (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) item	Sep. 30, 2024 USD ($) entity	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)
Number of real estate entities consolidated	2	2
Fixed assets	$ 78,246,467	$ 78,246,467	$ 81,387,649
Other assets	767,942	767,942	431,135
Liabilities	358,710,179	358,710,179	319,139,391
Equity attributable to noncontrolling interests	$ 19,337,732	$ 19,337,732	$ 17,652,916
Real Estate Entities
Cash				$ 1,000,000
Fixed assets				8,400,000
Other assets				200,000
Liabilities				5,400,000
Equity attributable to noncontrolling interests				$ 4,300,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Millions	Nov. 06, 2024 USD ($) shares
Subsequent Events
Common stock issued for exercise of warrants (in shares) | shares	219,996
Common stock issued for exercise of warrants | $	$ 1.2